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Abstract: Zusammenfassung Autoimmunkrankheiten gehören zu den schwersten Formen chronischer
Krankheiten in der westlichen Welt. Bei diesen Krankheiten wendet sich das körpereigene Immunsys-
tem gegen verschiedene Organe im Körper. Bis heute sind die Ursachen für diese Krankheiten weitge-
hend unbekannt und die Therapieoptionen sehr beschränkt. Es werden meist immunmod- ulierende
Substanzen verwendet, welche das gesamte Immunsystem supprimieren, aber die Krankheit nicht heilen
können. Eine neue Klasse von Medikamenten, für welche klinis- che Studien laufen, sind monoklonale
Antikörper, die nicht mehr das gesamte Immunsys- tem modulieren sondern nur eine gewisse Zellpopu-
lation des Immunsystems dezimieren. Es besteht die Hoffnung, dass die nach der Therapie vom Körper
neu produzierten Zellen den autoimmunen Charakter verlieren. Einer dieser Antikörper (Rituximab)
wendet sich gegen die B Zellen und führt zu einer Zer- störung dieser Zellen. Rituximab wurde für die
Krebstherapie entwickelt und wird heute auch bei Autoimmunkrankheiten verwendet. Es zeigte sich,
dass gewisse Patienten mit Autoim- munkrankheiten stark von dieser Therapie profitieren können. Der
genaue Wirkungsmecha- nismus zwischen der Zerstörung der B Zellen durch Rituximab und der daraus
folgenden Besserung des Krankheitsverlaufs ist bis heute unbekannt. In der vorliegenden Studie ver-
suchten wir herauszufinden, welcher Mechanismus diesem Zusammenhang zugrunde liegt. Hierfür haben
wir die Immunglobulinsequenzen von Patienten mit anti-Myelin-assoziiertes- Glykoprotein Neuropathie
(anti-MAG Neuropathie) vor und nach Gabe von Rituximab unter- sucht. Anti-MAG Neuropathie ist
eine Autoimmunkrankheit des peripheren Nervensystems (PNS), welche sich in Patienten mit anti-MAG
IgM Antikörpern entwickelt und zum Verlust der Nervenimpulsübertragung im PNS führt. Zur Analyse
der Immunglobulinsequenzen haben wir eine Einzelzellen PCR verwendet, welche uns erlaubt die En-
twicklung und Veränderung des B Zell Repertoires unter dem Einfluss von Rituximab zu untersuchen.
Wir sortierten jeweils drei verschiedene B Zellengruppen vor und 12 Monate nach der Therapie. Die B
Zellengrup- pen zeigten unterschiedliche Entwicklungsstufen und waren aufgeteilt in naïve, IgM memory
und IgG memory B Zellen. Wir verglichen die Resultate innerhalb der anti-MAG Neuropathie- Gruppe
zwischen mit Placebo und mit Rituximab behandelten Patienten, wie auch zwischen Patienten, die auf
die Therapie ansprachen und solchen, die nicht ansprachen. Als Kontrolle verwendeten wir eine dem Alter
angepasste gesunde Patientengruppe. Mit dieser Studie konnten wir zeigen, dass anti-MAG Neuropathie
Patienten eine grosse Expansion von IgM memory B Zellen, welche MAG erkennen, im Blut haben.
Patienten, welche auf die Therapie ansprachen zeigten kleinere Expansionen vor und nach der Behan-
dlung verglichen mit therapieresistenten Patienten. Des Weiteren fanden wir eine klonale Persistenz, eine
statische Situation in der Mutationsfrequenz der variablen Region der IgM Antikörper bevor und nach
der Therapie und ein Nichtvorhandensein der B Zell Maturierung- scheckpoints in den therapieresistenten
Patienten. Aus diesen Daten schliessen wir, dass der Therapieerfolg davon abhängt wie gut die zirkuli-
erenden pathogenen IgM memory B Zellen ausgelöscht werden können. Die effiziente Auslöschung führt zu
einer Neukonfigurierung des Immunsystems, welches sich in einer Reetablierung der Checkpoints äussert
und der Reduktion der pathogenen IgM Antikörper. Summary Autoimmune diseases include some of the
most severe chronic diseases in the western world. In autoimmune diseases the immune system of the
host attacks itself. Yet the underly- ing cause of most autoimmune mediated conditions is not completely
understood and the de- velopment of efficient treatments is still ongoing. Different drugs have been tested
for treating these kinds of diseases. Most of them primarily function in an anti-inflammatory manner,
are often accompanied by severe side effects and the chronicity of the conditions often doesn’t improve.
The lack of knowledge about the mechanism of action and the progression of the disease in most of these
patients led to numerous clinical trials alongside the establishment of new classes of drugs. In this work
a new class of drugs for the treatment of autoimmune dis- eases is analyzed. This new class comprises
antibodies, which do not suppress the immune system in general as is often done by old established
drugs. These therapies deplete certain populations of cells of the adaptive immune system. This study
focuses on the depletion of the B cells. The B cell-depleting IgG1 monoclonal antibody Rituximab can
persistently suppress disease progression in some patients with autoimmune diseases, but the mechanism
has remained unclear. In this study the Ig gene usage in a group of patients with anti-myelin-associat-
ed glycoprotein (MAG) neuropathy, an autoimmune disease of the peripheral nervous sys- tem, which
develops in individuals with an IgM monoclonal gammopathy and is mediated by IgM autoantibodies
binding to the MAG antigen was evaluated. Single cell sorted naïve, IgM memory and IgG memory B
cells were analyzed before and 12 months after treatment initiation and compared to age-matched healthy
controls. Patients with anti-MAG neuropathy showed substantial clonal expansions of blood IgM mem-
ory B cells which recognized MAG antigen. The group of patients showing no clinical improve- ment
following Rituximab therapy could be distinguished from clinical responders through a higher load of
clonal IgM memory B cell expansions before and after therapy, the persis- tence of clonal expansions
despite efficient peripheral B cell depletion, the lack of significant changes in somatic hypermutation
frequencies of IgM memory B cells and the lack of newly reestablished checkpoints in IgM memory and
IgG memory compartments. We infer from these data that the beneficial long-term immunomodulatory
effect of Rituximab therapy de- pends on efficient depletion of both circulating and non-circulating B cells
and is associated with qualitative immunological changes that indicate reconfiguration of B cell memory
through sustained reduction of autoreactive clonal expansions and the reestablishing of checkpoints for
the controlling of the B cell maturation.
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Autoimmunkrankheiten gehören zu den schwersten Formen chronischer Krankheiten in der 
westlichen Welt. Bei diesen Krankheiten wendet sich das körpereigene Immunsystem gegen 
verschiedene Organe im Körper. Bis heute sind die Ursachen für diese Krankheiten weitge-
hend unbekannt und die Therapieoptionen sehr beschränkt. Es werden meist immunmod-
ulierende Substanzen verwendet, welche das gesamte Immunsystem supprimieren,  aber 
die Krankheit nicht heilen können. Eine neue Klasse von Medikamenten, für welche klinis-
che Studien laufen, sind monoklonale Antikörper, die nicht mehr das gesamte Immunsys-
tem modulieren sondern nur eine gewisse Zellpopulation des Immunsystems dezimieren. Es 
besteht die Hoffnung, dass die nach der Therapie vom Körper neu produzierten Zellen den 
autoimmunen Charakter verlieren.
Einer dieser Antikörper (Rituximab) wendet sich gegen die B Zellen und führt zu einer Zer-
störung dieser Zellen. Rituximab wurde für die Krebstherapie entwickelt und wird heute auch 
bei Autoimmunkrankheiten verwendet. Es zeigte sich, dass gewisse Patienten mit Autoim-
munkrankheiten stark von dieser Therapie profitieren können. Der genaue Wirkungsmecha-
nismus zwischen der Zerstörung der B Zellen durch Rituximab und der daraus folgenden 
Besserung des Krankheitsverlaufs ist bis heute unbekannt. In der vorliegenden Studie ver-
suchten wir herauszufinden, welcher Mechanismus diesem Zusammenhang zugrunde liegt. 
Hierfür haben wir die Immunglobulinsequenzen von Patienten mit anti-Myelin-assoziiertes-
Glykoprotein Neuropathie (anti-MAG Neuropathie) vor und nach Gabe von Rituximab unter-
sucht. Anti-MAG Neuropathie ist eine Autoimmunkrankheit des peripheren Nervensystems 
(PNS), welche sich in Patienten mit anti-MAG IgM Antikörpern entwickelt und zum Verlust der 
Nervenimpulsübertragung im PNS führt. Zur Analyse der Immunglobulinsequenzen haben wir 
eine Einzelzellen PCR verwendet, welche uns erlaubt die Entwicklung und Veränderung des 
B Zell Repertoires unter dem Einfluss von Rituximab zu untersuchen. Wir sortierten jeweils 
drei verschiedene B Zellengruppen vor und 12 Monate nach der Therapie. Die B Zellengrup-
pen zeigten unterschiedliche Entwicklungsstufen und waren aufgeteilt in naïve, IgM memory 
und IgG memory B Zellen. Wir verglichen die Resultate innerhalb der anti-MAG Neuropathie-
Gruppe zwischen mit Placebo und mit Rituximab behandelten Patienten, wie auch zwischen 
Patienten, die auf die Therapie ansprachen und solchen, die nicht ansprachen. Als Kontrolle 
verwendeten wir eine dem Alter angepasste gesunde Patientengruppe. 
Mit dieser Studie konnten wir zeigen, dass anti-MAG Neuropathie Patienten eine grosse 
Expansion von IgM memory B Zellen, welche MAG erkennen, im Blut haben. Patienten, 
welche auf die Therapie ansprachen zeigten kleinere Expansionen vor und nach der Behan-
dlung verglichen mit therapieresistenten Patienten. Des Weiteren fanden wir eine klonale 
Persistenz, eine statische Situation in der Mutationsfrequenz der variablen Region der IgM 
Antikörper bevor und nach der Therapie und ein Nichtvorhandensein der B Zell Maturierung-
scheckpoints in den therapieresistenten Patienten. 
Aus diesen Daten schliessen wir, dass der Therapieerfolg davon abhängt wie gut die zirkuli-
erenden pathogenen IgM memory B Zellen ausgelöscht werden können. Die effiziente 
Auslöschung führt zu einer Neukonfigurierung des Immunsystems, welches sich in einer 
Reetablierung der Checkpoints äussert und der Reduktion der pathogenen IgM Antikörper.
Zusammenfassung
4
Autoimmune diseases include some of the most severe chronic diseases in the western 
world. In autoimmune diseases the immune system of the host attacks itself. Yet the underly-
ing cause of most autoimmune mediated conditions is not completely understood and the de-
velopment of efficient treatments is still ongoing. Different drugs have been tested for treating 
these kinds of diseases. Most of them primarily function in an anti-inflammatory manner, are 
often accompanied by severe side effects and the chronicity of the conditions often doesn’t 
improve. The lack of knowledge about the mechanism of action and the progression of the 
disease in most of these patients led to numerous clinical trials alongside the establishment of 
new classes of drugs. In this work a new class of drugs for the treatment of autoimmune dis-
eases is analyzed. This new class comprises antibodies, which do not suppress the immune 
system in general as is often done by old established drugs. These therapies deplete certain 
populations of cells of the adaptive immune system. This study focuses on the depletion of 
the B cells.
The B cell-depleting IgG1 monoclonal antibody Rituximab can persistently suppress disease 
progression in some patients with autoimmune diseases, but the mechanism has remained 
unclear. In this study the Ig gene usage in a group of patients with anti-myelin-associat-
ed glycoprotein (MAG) neuropathy, an autoimmune disease of the peripheral nervous sys-
tem, which develops in individuals with an IgM monoclonal gammopathy and is mediated 
by IgM autoantibodies binding to the MAG antigen was evaluated. Single cell sorted naïve, 
IgM memory and IgG memory B cells were analyzed before and 12 months after treatment 
initiation and compared to age-matched healthy controls. 
Patients with anti-MAG neuropathy showed substantial clonal expansions of blood IgM mem-
ory B cells which recognized MAG antigen. The group of patients showing no clinical improve-
ment following Rituximab therapy could be distinguished from clinical responders through 
a higher load of clonal IgM memory B cell expansions before and after therapy, the persis-
tence of clonal expansions despite efficient peripheral B cell depletion, the lack of significant 
changes in somatic hypermutation frequencies of IgM memory B cells and the lack of newly 
reestablished checkpoints in IgM memory and IgG memory compartments. We infer from 
these data that the beneficial long-term immunomodulatory effect of Rituximab therapy de-
pends on efficient depletion of both circulating and non-circulating B cells and is associated 
with qualitative immunological changes that indicate reconfiguration of B cell memory through 
sustained reduction of autoreactive clonal expansions and the reestablishing of checkpoints 
for the controlling of the B cell maturation. 
Summary
5
The human immune system displays a striking similarity to that of other vertebrates. It is comprised of 
a complex and elegant network of numerous humoral and cellular components, which originate from 
hematopoietic stem cells (HSC) located in the bone marrow. The HSC generate two different kinds of 
immune cells. The innate immune cells defend the host immediately against pathogens by recognition 
of pathogen-associated molecular patterns (PAMPS). The second group of cells, which are differentiat-
ed from HSC are adaptive immune cells namely B and T cells. These cells have the ability to perform a 
highly	specific	response	and	additionally	develop	immunological	memory	against	a	specific	pathogen.
The blood stream and the lymphatic system are the major distributors of the immune system and 
connect the lymphoid organs with each other as well as the periphery with the immune system. 
Lymphoid	organs	are	the	sites	of	immune	cells	differentiation,	maturation	and	further	development.	
Vertebrates	have	primary	and	secondary	lymphoid	organs	with	specific	functions.	The	bone	marrow	
and the thymus constitute the primary lymphoid organs in adult humans. These organs possess the ca-
pacity to differentiate progenitor cells into different hematopoietic cell lineages (Figure 1). Most blood 
cells are generated in the bone marrow with the prominent exception of T cells, which develop from 
bone marrow derived precursors and mature in the thymus. 
To reach the circulation immune cells have to differentiate through several precursor stages. This holds 
true for innate and adaptive immune cells as well for platelets and red blood cells.
 
Next page: The hierarchy of the blood cell development is illustrated from the top to the 
bottom. Different precursors are depicted with colored nuclei and two major pathways are 
shown. The myeloid cells are shown on the left and the lymphoid cells on the right side. 
The figure is adapted from 1-2
Introduction
Figure 1: The development of different hematopoietic cells
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The maturation steps have to be controlled and supported by surrounding cells such as stromal cells, 
which secret factors like chemokines, growth factors and interleukins to control the development of the 
precursor cells. The precursor cells do secret similar factors but with a different signature. This leads 
to a complex system of inhibition, activation as well as positive and negative feedback loops. In case 
one of these interactions is disturbed the system becomes deregulated and may start to attack the host 
instead of protecting it. 
For a better overview of the different layers of self-tolerance see Table1. In recent years several 
discoveries have been made as of how this network interacts to protect the host from pathogens while 
retaining self-tolerance. One crucial step is the discrimination of self and non-self . This mechanism 
is based for T cells on the presentation of self-peptides on major histocompatibility complex (MHC) 
molecules, which are expressed on almost all nucleated cells (class I) and antigen presenting cells like 
B cells, macrophages and dendritic cells (class II) . Downregulation of MHC class I as occurring upon 
virus infection or tumor transformation leads to elimination of the cell via cytotoxic natural killer (NK) 
cells 3,4. 
Layers of self-tolerance
Type of tolerance Mechanism Site of action
Central tolerance Deleting editing Thymus T cells
Bone marrow B cells
Antigen segregation Physical barrier to self-
antigen access to lymphoid 
system
Peripheral organs
(e.g. thyroid, pancreas)
Peripheral anergy Cellular inactivation by 
weak signaling without co-
stimulus
Secondary lymphoid tissue
Regulatory cells Suppression by cytokines 
intracellular signals
Secondary lymphoid tissue 
and site of inflammation
Cytokine deviation Apoptosis post-activation Secondary lymphoid tissue 
and site of inflammation
Clonal deletion Apoptosis post-activation Secondary lymphoid tissue 
and site of inflammation
Summary of the different checkpoints in the development of the adaptive immune system.
Table addapted from2
Table 1:  The different checkpoints in the development of lymphocytes
8
On the other hand the adaptive immune system, which generates a broad diversity of antigen recep-
tors in a random way, has to learn to distinguish self and non-self to reach self-tolerance. Adaptive 
T/B	cells	have	to	pass	tight	selection	checkpoints	for	testing	the	newly	generated	antigen	receptors	for	
self-reactivity and functionality to further develop. These are important steps in the maturation of these 
cells and can protect the host from autoimmune diseases (see p18). 
One	crucial	element	in	the	adaptive	immune	system	is	the	occurrence	of	two	random	site-specific	DNA	
recombination events, which are called V(D)J recombination, during which the antigen receptor is 
created 5,6. 
FWR1≈75bp FWR2≈51bp FWR3≈114bp
CDR1 CDR3CDR2
D J constant region µ,δ,γ,ε,α
variable region≈295bp
Variable gene segments (VH) Diversity gene segements (DH) Joining gene segments (JH)
constant region µ,δ,γ,ε,α
D to J recombination
V to DJ reombination
constant region µ,δ,γ,ε,α
constant region µ,δ,γ,ε,α
P and N nucleotide 
addition
The VH gene element is depicted in green, DH in blue and JH in pink. The different segments 
are the repetitive boxes of the same color. First, the DH and JH recombine and excise the sur-
plus gene segments. Next, the VH element recombines with the DJH element. After these two 
recombinations the variable region is generated, which encode for two secondary structure 
elements. The β sheet (FWR) and in orange loops (CDR) are depicted in green and orange, 
respectively. The figure is adapted from 2
Figure 2: The distribution of the three different gene elements VH, DH, and 
     JH of the heavy chain 
9
The receptor is generated through a random combination of one variable V, a diversity D and a join-
ing	J	segment	(Figure	2).	The	first	recombination	is	the	VDJ	recombination	of	the	heavy	chain	for	B	
cells	or	α/γ-chain	for	T	cells	followed	be	the	VJ	recombination	of	the	light	chain	(B	cell)	or	β/δ	-chain	
(T	cell)	(see	p15).	Together	the	heavy	and	light	chains	form	the	B	cell	receptor	(BCR)	and	the	α/β	or	
γ	/δ	the	T	cell	receptor	(TCR).	In	the	case	of	B	cells	these	events	generate	a	theoretical	variation	of	 
1.9*106 different variable region on the (BCR). The variable region of the BCR is the part of the re-
ceptor,	which	binds	the	antigen	and	therefore	defines	part	of	the	binding	properties	of	the	BCR	and	its	
secreted form, the antibody (Figure 3). The BCR is the sensor that guides the B cells through the dif-
ferent maturation steps, which start in the bone marrow, proceed in the secondary lymphoid organs and 
finally	may	end	as	an	antibody	secreting	plasma	cells	back	in	the	bone	marrow	(Figure	4).			
B lineage cells generate antibodies against epitopes of antigens and neutralize these via a high 
binding	affinity.	This	is	achieved	by	the	combined	structure	of	both	variable	regions	from	the	heavy	
and	light	chain.	The	structure	of	the	variable	region	has	a	β-sheet	framework	with	three	loops	called	
the complementary determining regions (CDR1, CDR2, CDR3). These CDRs are highly variable and 
are mainly involved in binding their respective antigen7 through van der Waals force, hydrogen- and 
ionic bonds. Especially the CDR3, which is the loop with the highest variable amino acid composition 
and length, is primarily involved in the binding 8. But it is not exclusively the V(D)J recombination 
that generates the high variability and ultimately the avidity of the antibodies. In the vertebrate immune 
system	an	interaction	of	both	adaptive	immune	cells	(B/T	cells)	and	innate	immune	cells	diversifies	the	
variable region of the BCR. This mechanism is called somatic hypermutation (SHM) and introduces 
mutations in the variable region of the antibody especially so in the CDRs. These mutations are chang-
ing the avidity of the antibody. Due to positive selection, the avidity increases and the antibody reaches 
a stronger binding avidity towards the antigen. The process of the SHM takes place in the germinal 
center (GC) of the secondary lymphoid organs (see p25). 
Antibodies have a very important function in the immune system and link the adaptive part with the 
innate	immune	system	due	to	the	variable	part	and	its	specific	avidity	towards	a	particular	antigen	
and	the	different	modification	in	the	constant	region,	which	is	called	fragment	crystallizable	region	or	
Fc that can be introduced by the class switch recombination (see p23). The constant part is called the 
isotype. The isotype regulates the signals that are sent to the rest of the immune system, modulates 
stability (half-life), neutralization, opsonization, complement activation as well the trans tissue  
transport. Antibodies have different ways to signal to the immune system, which differ between the 
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An antibody contains two major parts, a constant part (depicted in blue CL, CH1, CH2 and 
CH3) and a variable part (labeled in green VL and VH), which recognizes the target antigen. 
The variable part consists of two protein chains one from the light and one from the heavy 
chain, which together form the binding site. The diversity and the recognition of an antigen 
are due to the V(D)J recombination of heavy and light chain and the different combinations 
that can be achieved. The complementary determined regions (CDR) are formed via this re-
combination (depicted in orange, and yellow). These highly variable parts are mainly involved 
in the binding of antigen. Figure is adapted from THE INTERNATIONAL IMMUNOGENET-
ICS INFORMATION SYSTEM www.IMGT.org
Figure 3: The structure of an IgG antibody:
isotype	classes.	In	humans	five	different	isotype	classes	are	to	be	found	(IgM,	IgD,	IgE,	IgG,	IgA)	9. 
The different interactions with the rest of the immune system is listed in the Table 2 .
Since B cells undergo the VDJ recombination and SHM in the different maturation steps it is likely 
that a mal-function in one of the checkpoints for self-tolerance can lead to an autoimmune diseases 12. 
There are actually several autoimmune diseases linked to autoantibodies including Rheumatoid arthri-
tis,	Neuromyelitis	optica,	Myasthenia	gravis,	Systemic	lupus	erythematosus	(SLE),	Primary	Sjögren’s	
syndrome, Ideopathic thrombocytopenic purpura, Autoimmune hemolytic anemia, Cold agglutinin 
disease,	Cryoglobulinemia,	ANCA-associated	vasculitis,	Pemphigus	vulgaris,	Graves’	disease,	Anti-
MAG neuropathy.
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Isotypes Structure g/l Specialty
IgM Pentamer 1.5 Initial antibody class, does not require class switch. 
Binds viral particles and complement
IgD Monomer 0.04 Only expressed on cell surface, e.g. transmembrane  
Ig molecule
IgG Monomer 10 Most abundant class with four isotype subclasses- IgG1, 
IgG2, IgG3, IgG4. Binds to the Fc receptors on mono-
cytes, B cells, NK
  IgG1 Monomer 9 Second most effective complement activator after IgG3, 
mediates opsonization
  IgG2 Monomer 3 Weak complement activator
  IgG3 Monomer 1 Most effective complement activator, mediates opsoniza-
tion
  IgG4 Monomer 0.5 Cannot activate complement, mediates opsonization 
with intermediate affinity for Fc (Fragment crystallizable) 
receptors
IgA Monomer/
Dimer
2.1 Mainly secreted in mucosa, gastrointestinal tract and 
tears. Inhibits attachment of pathogens to mucosal cells.
  IgA1 Dimer Present in blood as monomer and as dimer or oligomer 
in the mucosa
  IgA2 Monomer Present in blood as monomer and as dimer or oligomer 
in the mucosa
IgE Monomer 3*10-5 Binds to Fc receptors on basophiles and mast cells 
inducing degranulation. Accounts for hypersensitivity 
reactions (allergies). Found mainly in tissues
Modified from 2,10,11
Table 2: Properties and biological activities of human Ig isotype classes
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Since the anti-MAG neuropathy is a clearly an antibody mediated disease the following parts will fo-
cus on the different B cell linages B1 and B2 B cells and the distinctive developmental features of B2 
B cells starting from the bone marrow too different effector linages. The pathway and checkpoints for 
B	cell	development	are	summarized	in	Figure	4.	The	next	chapter	starts	with	the	first	step	in	the	life	of	
B cells, which is the VDJ recombination of the BCR.
 
The maturations of the B cells is illustrated from left to the right. There are two different 
kinds of B cells the B1 and the B2 B cells, which have different lymphoid progenitor cells. 
The development starts in the bone marrow and ends as memory B cell and plasma cell 
for the B2 B cells. The B2 B cells have different ways to enter the memory compartment. 
One is T cell- dependent and takes place in the germinal center and the other route is 
T cell-independent (TI). The TI pathway takes place in the marginal zone of the spleen and 
the gut. Regarding the B1 B cells not much is known as of how they develop. Unknown de-
velopmental steps are indicated with a question mark (?). B cell checkpoints are indicated 
with a red line. Dotted arrows reflect origin of estimated precursor. Figure is adapted from13-15
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For the adaptive immune system recombination of a unique receptor for pathogen recognition is a 
key	step	in	the	development.	For	B	cells	this	receptor	(BCR)	is	used	for	the	specific	recognition	of	
an epitope of an antigen. The construction of the BCR involves double strand breaks (DSB) of the 
DNA and re-ligation with a different part of the DNA. This event is named V(D)J recombination or 
site-specific	DNA	recombination	(SSR)	16-18. The genetic information for the BCR is located on dif-
ferent chromosomes, namely 14 for the heavy chain (IgH) 19, 2 for the kappa light chain (IgK) 20,21 
and	22	for	 the	 lambda	light	chain	(IgL)	 21,22. This has the advantage that the recombination site for 
each chain is located spatially independent from each other and do not interfere with the sequential 
intra-chromosomal recombination events. 
The	first	V(D)J	 recombination	 in	B	 cells	 starts	with	 the	 heavy	 chain	 at	 the	 early	 pro-B	 cell	 stage	
and recombines in a random selection one diversity IGHD with one joining IGHJ element 23 fol-
lowed by an additional V(D)J recombination, where one variable IGHV segment is ligated with the 
already combined DJ segments and build together the exon of the variable region of the BCR heavy 
chain. A successful in-frame heavy chain recombination suppresses further recombination of the 
second chromosome 14. This control mechanism is called allelic exclusion. In the pre-B cell stage 
the V(D)J recombination for the light chain starts, which only recombines variable and joining seg-
ments	to	form	the	variable	region	of	the	light	chain	.	Light	chain	recombination	starts	with	the	kap-
pa light chain. If this V(D)J recombination for the kappa light chain is successful the lambda light 
chain recombination is suppressed. This mechanism is called isotype exclusion 24. In the case of a 
non-functional/autoreactive	kappa	light	chain	the	lambda	light	chain	is	recombined	and	the	kappa	light	
chain locus is silenced via the kappa deletion element (KDE) 25.	The	KDE	is	located	3’	downstream	of	
the constant region of the kappa light chain. The locus is then silenced through the recombination of the 
KDE	with	either	Jκ	or	Vκ,	which	leads	to	an	excised	constant	region	and	silencing	of	the	kappa	light	
chain . The allelic exclusion for the light chain is not yet understood. The high diversity of the variable 
region is generated by the numerous variable, diversity and joining segments, which are placed next 
to each other on the chromosome. Due to close sequence homologies of some IGHV, IGHD and IGHJ 
segments these segments can be summarized as families 26.
For the heavy chain of an antibody 123-129 different immunoglobulin heavy chain variable gene seg-
ments	(IGHV)	are	known,	deriving	from	7	different	families.	Of	these	IGHV	segments	79	are	classified	
as pseudogenes and 43 as functional. 
V(D)J recombination
14
VH family
Classification VH 1 VH 2 VH 3 VH 4 VH 5 VH 6 VH 7 Total
Functional 9 3 19 6 1 1 0 39
Transcribed 0 0 0 1 0 0 0 1
Open reading 
frame
0 0 3 0 0 0 1 4
Pseudogene
Point mutation
Truncation 3 1 21 2 0 0 2 29
Total 2 0 22 23 1 0 2 50
14 4 65 32 2 1 5 123
The table sorts the 123 VH segments that are located on the chromosome 14 into the different 
families and by functionality. The table is adapted from 26
While the IGHV-3 family is the largest one followed by IGHV-1 and IGHV-4 (Table 3)
Of the diversity elements IGHD 27 segments exist and can be grouped into 7 different fami-
lies and for IGHJ element 9 segments were found, which can be summarized into 6 families 26. 
Since there are three different elements and at least 43 IGHV, 27 IGHD and 9 IGHJ segments the cells 
have to discriminate between the variable, diversity and joining elements to avoid the combination 
of joining and variable segments in the case of the heavy chain. To prevent this mistake the ligation 
of	the	different	gene	elements	is	directed	by	a	specific	recombination	signal	sequence	(RSS).	These	
sequences	are	flanking	the	coding	sequence	of	the	IGHV,	IGHD	and	IGHJ	segments.	RSS	do	have	a	
special architecture of a conserved palindromic heptamer sequence spaced by 12 or 23 bases from a 
second conserved nonamer sequence, which lead to the name 12- or 23-RSS. 
Each	gene	segment	has	a	12-	or	23	RSS.	The	SSR	follows	the	12/23	rule	where	only	segments	with	
12 bp spaces can be fused to 23 bp spaced segments 27. During the recombination several proteins as-
semble	on	the	DNA	and	loop	out	the	DNA	to	form	a	synaptic	complex	(Figure	5B).	The	first	proteins	
are the DNA-binding high-mobility group box (HMGB) proteins 1 and 2 28. These proteins bind in the 
minor grove of the 23 RSS and prepare the binding of the most important proteins RAG1 and RAG2 
to the 12-and 23 RSS (Figure 5 A and B) 29,30. The binding of RAG1 and RAG2 proteins to the DNA 
synergistically	increases	the	binding	affinity	and	initiates	a	DNA	double	strand	break	6,31.
Table 3: Human VH segments found on the chromosome 14
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variable gene segments diversity gene segement joining gene segments
constant region µ,δ,γ,ε,α
5’ 3’
5’3’
12 RSS 23 RSS
5’
3’
5’
3’
5’
3’
5’
3’
OH 3’
OH 3’
5’
3’
5’
3’
trans-esterification and 
hairpin formation 
5’
3’
5’
3’
5’
3’ 5’
3’
MRE11
RAD50
NBN
complex
MRN 
complex
5’
3’ 5’
3’
5’
3’ 5’
3’
Artemis
DNA-PKcs
Ku70, Ku80
DNA ligase IV
XRCC4
TdT, Polymerase µ and λ
XLF
HMGB 1 and 2
RAG 1 and 2
3’ RAG1/2 complex 
single strand break
stabelising of the coding strand
via MRN comlex
DNA-PKcs, Ku70,Ku80
artemis assambles
HMGB1/2 assambles on the DNA
minor grove at the 23RSS
RAG1/2 assambles and binds to the 
12-and 23 RSS
artemis nicks the hairpin DNA
1-2 bp 5’ from the tip
ligation by XLF XRCC4 and 
DNA lagise IV 
N nucleotide addition by TdT
liagtion of the exised DNA via
XLF XRCC4 and 
DNA lagise IV
A)
B)
C)
D)
E)
F)
G)
H)
J)
VH DH JH
Form the top to the bottom the sequential events of the DNA recombination are depicted. A) 
The first step is the binding of HMGB1/2 to the 23SSR. B) The binding of the HMGB facilitates 
the binding of RAG1/2, which loops the remaining DNA out. C) RAG1/2 introduce a 3’ single 
strand break. D) The 3’ hydroxyl group binds to the antisense DNA and generates a loop. E) 
The two coding segments are stabilized via the MRN complex. F) Ku70, Ku80, DNA PKcs 
and Artemis assemble on the hairpin loop. G) Artemis cleaves the hairpin and generates a 
5’ overhang at the coding DNA strand. H) TdT and polymerases µ and λ fill up the gaps and 
DNA ligase IV, XRCC4 and XLF ligate the DNA together. J) The ligation of the excised DNA 
via DNA ligase IV, XRCC4 and XLF is illustrated. The figure is adapted from 13,32
Figure  5: The DNA recombination machinery
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In the process of the DNA double strand break (DSB) two sequential events occur 33.	The	RAG1/2	
complex	 introduces	 a	 single	 strand	 break	 (SSB)	 at	 the	 3’	 end	 of	 the	DNA,	which	 leads	 to	 a	 free	 
3’	OH	group	at	the	gene	segment	(Figure	7B	and	C).	The	3’	hydroxyl	group	is	further	processed	into	a	
hairpin loop via a direct trans-esterification	34,35, which leads to blunt ends of the excised DNA (Figure 
5D). The hairpin of the coding segments are stabilized via	a	complex	consisting	of	MRE11,	RAD50	
and NBN named MRN complex) (Figure 5E) 36-39.	Additional	factors	are	assembled	to	the	RAG1/2	
DNA	complex	 namely	Ku70,	Ku80,	XRCC4,	DNA-Ligase4,	XLF,	DNA-dependent	 protein	 kinase	
(DNA-PKcs) and Artemis 40-45. The excised blunt end DNA is then ligated by the common mecha-
nism non-homologous DNA end-joining NHEJ via	the	XLF	XRCC4	DNA-Ligase4	complex,	which	 
connects the excised DNA to a circle 45 (Figure 5 F and J).
The	DNA-PKcs	Artemis	complex	opens	the	hairpin	of	the	DNA	1-2	bp	5’	away	from	the	tip	of	the	
hairpin	and	generates	a	palindromic	overhang	up	to	4	bp	(P-element)	at	the	5’	end	of	the	coding	DNA	
(Figure 5 F to G) 40,46.	Polymerase	µ	and	λ,	as	well	as	the	terminal	deoxynucleotidyl	transferase	(TdT)	
are	recruited	and	fill	the	cap	with	non-template-encoding-nucleotides	(N-elements).	While	Polymerase	
λ	can	only	fill	in	caps	in	a	template	dependent	manner,	TdT	and	with	less	activity	Polymerase	µ	are	able	
to add nucleotides in a template-independent way 47-49.	Finally	the	DNA	ends	are	ligated	with	the	XLF	
XRCC4	DNA-Ligase4	complex	(Figure	5	G	and	H).
If the V(D)J recombination of the heavy chain is functional, the pro-B cells are positively selected by 
testing for the BCR expression enter a small proliferation round13. Then, after one to two cell divisions, 
the B cells slightly induces the V(D)J recombination for the light chain. Finally the fully functional 
BCR has to undergo numerous rounds of positive and negative selections, until the B cells are allowed 
to	produce	antibodies	with	the	specificity	of	the	BCR.	These	selection	points	are	named	checkpoints	
and the next chapter is focusing on these events during the B cell development.
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Galectin-1 crosslinks the pre-BCR of the pre-B-II cell via binding to λ14.1 on the pre-BCR 
and integrins on the stromal and B cell, this provides four main signals to the pre B II. (i) the 
cell receives a signal for proliferation, which lead to 1-2 cell divisions. (ii) At the same time the 
signal for the allelic exclusion is provided (iii) and the proliferation stops and (iv) the light chain 
VJ recombination starts. Figure adapted from 13
To ensure that developing B cells are functional and self-tolerant the cells have to pass positive and 
negative selection checkpoints. Positive selection always includes steps where the BCR binds an an-
tigen, clusters and sends signals to the cells. These selections lead to survival of the cells. In the case 
of negative selection the cells only survive if the BCRs are not cross-linked and do not signal to the 
nucleus. The high diversity of antibody recombination needs a discrimination of self and non-self to 
protect	the	host	from	autoantibody	mediated	diseases.	This	idea	dates	back	to	Paul	Ehrlich	in	1902,	
when	he	first	formulated	the	hypothesis	of	horror autotoxicus. He postulated that an immune system, 
which is not able to distinguish between self and non-self is connected to certain human diseases. To-
day the sites of the checkpoints to protect the host from autoimmune diseases are known and some of 
the selection mechanisms as well. This chapter will mainly focus on the different checkpoints, which 
are in involved in the B cell development.
Figure 6: The positive selection of the pre B 2 cell after the heavy chain VDJ recombination
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The	first	selection	in	the	life	of	B	cells	is	a	positive	selection	after	the	successful	VDJ	recombination	
and expression of a functional heavy chain. The expression of the heavy chain has to be tested in the 
bone marrow to provide the cells with further survival and proliferation signals. The stromal cells in 
the bone marrow have the capability to check the pre-B-II cells for the heavy chain expression. Pre-
B-II cells express a pre-BCR bound on the cell membrane composed of the newly recombined heavy 
chain	and	instead	of	a	κ	or	λ	light	chain	two	special	proteins	called	VpreB	and	λ14.1	(also	called	λ5).	
Taking	the	roles	of	signaling	proteins	CD79A	(Igα)	and	CD79B	(Igβ)	are	clustered	to	the	receptor	50,51. 
To test the expression of the heavy chain, stromal cells are secreting Galectin-1, which is able to bind 
to	the	λ14.1	on	pre-B-II	cells	and	at	the	same	time	to	α4β1	α5β1	α4β7	integrins	on	the	pre-B-II	and	
stromal cells 52-54. The binding of Galectin-1 to the stromal cell and the pre-B-II cells leads to cluster-
ing	of	the	pre-BCR	that	finally	induces	a	signal	for	survival	54,55 (Figure 6). It is very important for 
precursor-B cells to check the signal capacity of the BCRs for the further maturation and selection 
steps of the B cells 13.
After this positive selection the recombination of the light chain starts. As already mentioned 
above	 there	 are	 two	 different	 light-chains	 present	 namely	 κ	 and	 λ.	 Interestingly,	 the	 light	 chains	
are	not	expressed	in	equal	amounts,	but	there	is	a	clear	bias	towards	the	κ	light	chain	56. In humans 
the	κ/λ	 ratio	 is	 3/2	whereas	 it	 is	 20/1	 in	mice.	 In	 the	 case	of	 a	 λ	 light	 chain-positive	B	 cells	 both	 
kappa light chain loci are either not in frame or the produced light chain is autoreactive and deleted 
25.	This	 indicates	 that	 the	rearrangement	of	 the	λ	 light	chain	occurs	 later	 in	 the	B	cell	development	
than	 the	 κ	 light	 chain	 rearrangement	 25,57,58,	which	 gave	 a	 first	 hint	 for	 a	 negative	 selection	 at	 this	
stage of the B cell development (Figure7). Wardemann et. al could show that the replacement of a 
light chain in the case of an autoreactive antibody can reduced the reactivity to a model antigens 59. 
  
During early B cell development the process of rearranging the light chains to create new variants of 
the BCR is called receptor editing. This step is necessary if the newly formed BCR has a high avidity 
for self-antigens 59,61-65. Receptor editing is a frequent event in the development of pre-B-II cells in the 
bone	marrow.	Between	20-50%	of	all	developing	B	cells	undergo	receptor	editing	61. 
If the BCR crosslinks with the self antigen on the stromal cells a new round of light chain rearrange-
ment starts 66. Until today it is not known how the stromal cell present the autoantigen to the BCR of 
the immature B cells 66. First the second kappa allele is rearranged and if the BCR is still autoreactive 
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The checkpoints during the maturation of B cells lead to changes in the distribu-
tion of κ/λ light chains. Numbers express mean values +/- one standard deviation. 
The figure is adapted from 60
the lambda chain locus starts to rearrange 25,67.	Wardemann	showed	in	2003	that	more	then	70%	of	the	
antibodies expressed by early immature B cells show self-reactive binding to different model antigens 
like	ssDNA,	dsDNA,	LPS,	Insulin	and	HEp-2	cells	62.	About	45%	of	these	self-reactive	antibodies	can	
be silenced via light chain exchange 59. 
These	 self-reactive	 antibodies	 are	 further	 distinguished	 into	 two	 subgroups.	 The	 first	 subgroup	 is	
named	polyreactive	with	binding	to	ssDNA,	dsDNA	and	LPS	and	the	second	subgroup	is	referred	to	
as autoantibodies, which binds to protein-derived self-antigens like Insulin and stains the human cell 
line HEp-2 and binds to lysate of these cells. The strength of the checkpoint can be seen as an impres-
sive	drop	of	polyreactivity	from	55%	of	immature	B	cells	to	7%	in	the	T1,	T2	and	mature	naïve	B	cell	
stages in the blood (Figure 8) 62.
If the B cells still do not pass the autoreactivity test from the stromal cells due to BCR crosslinking 
with self-antigens on stromal cells, the cells will undergo apoptosis, turn into an anergic B cells or the 
cells have to undergo a new IgH VDJ recombination 68-71. However a new VDJ recombination is not 
that	trivial	because	all	the	12bp	RSS	were	deleted	on	one	or	both	alleles	during	the	first	recombination	
event 72-74. 
Figure 7: κ/λ ratio in different B cell lineages in humans
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Due to selection, the amount of immature B cells that are able to leave the bone marrow is very small. 
Only	10-20%	are	finally	ending	up	in	the	periphery	to	undergo	further	maturation.	This	strong	selection	
reduces the autoreactivity of the immature B cells by half 75,76 (Figure 8). However some autoreactive 
B cells do escape via the expression of two different light chains or two BCRs and in certain cases the 
B cells still express the V-pre-B light chain, which has an isoelectric point of 5.67 and might neutralize 
the positive charge of the heavy chain 77,78 thereby neutralizing positive charges of variable regions, 
which are thought to be responsible for the binding to negatively charged DNA 62. 
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BCR autoreactivity is reduced after passing the different checkpoints during the development 
of B cells: Different maturation stages of B cells were single-cell sorted and the individual an-
tibodies recombinantly expressed and tested for autoreactivity in an ELISA based on HEp-2 
lysate. There are decreases of the autoreactivity after each checkpoint and an increase after 
the GC reaction. This increase is due to SHM, which are randomly introduced in to the vari-
able region of the BCR. The graph was adapted from 75
Figure 8: BCR autoreactivity of B cell
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After immature B cells pass the checkpoints in the bone marrow they will migrate via the central si-
nus into the blood stream 79,80. In the blood the new emigrants mature via the transitional stage T1-T2 
towards	the	mature	naïve	stage	81-83. In mice and humans the immature T1 stage is present in the bone 
marrow, blood and spleen; while in mice the T2 stage is restricted to the spleen 84, in humans the T2 
stage is less stringently located to the spleen. T2 cells are able to develop outside of the spleen in sple-
nectomized humans 85.	Since	the	self-reactivity	of	the	new	emigrants	is	not	removed	sufficiently	yet,	
the B cells in the transitional stage have to pass an additional negative selection point in the spleen. 
Between	the	T1/T2	and	the	mature	naïve	stage	self-reactivity	is	reduced	again	by	half,	down	to	20%	
62,86 (Figure 8). Further evidence for a checkpoint comes from the differences in sensitivity of BCR 
crosslinking in the two different transition stages. T1 is highly sensitive for BCR crosslinking and 
undergoes	apoptosis.	T2	in	contrast	gets	activated	and	turns	in	a	mature	naïve	B	cell	phenotype	87,88.
After	the	checkpoint	in	the	spleen	the	T2	B	cells	further	develops	into	a	mature	naïve	B	cells.	What	the	
checkpoint is composed of is still under debate. Data from mice suggested that the signal strength of 
the BCR either induces survival or cell death in T1 B cells 89-92	and	an	involvement	of	FcγRIIB	93 and 
the	TNF-families	members	BAFF	and	APRIL	94 was also reported. BAFF signaling induces survival of 
B	cells	and	an	excess	of	BAFF/BAFFR	signaling	can	promote	the	survival	of	autoreactive	B	cells	95-97.
Mature	naïve	B	cells	can	develop	in	two	different	directions	 13. Either the cells mature T cell-inde-
pendently in the gut and the marginal zone of the spleen or the cells pass through the GC where they 
undergo follicular helper T cell (TFH) dependent maturation 
13. 
In the GC the B cells undergo the last checkpoints before entering the memory and plasma cell com-
partment 75.	Before	the	mature	naïve	B	cells	enters	any	of	the	three	pathways	they	have	to	be	activated	
by an antigen. Via Toll-like receptor engagement or BCR crosslinking with a multi-epitope antigen the 
mature	naïve	B	cells	can	mature	in	a	TI	way	98-102. Overexpression or activation of Toll-like receptors 
have the capability to rescue anti-DNA and -RNA autoreactive B cells from negative selection 103.
For a better representation of the two pathways I will split them in subchapters. One part sheds light on 
the	T	cell-dependent	affinity	maturation	in	the	germinal	centers	and	the	other	part	on	the	TI	maturation	
of the two linages CD27+IgA+ and marginal zone B cells (MZ). But before we start with the GC reac-
tion,	we	have	to	understand	the	class	switch	recombination,	which	is	a	very	important	step	in	the	final	
maturation of the B cell.
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In GC and in the gut the CD27+IgA2 B cells undergo class switch recombination to exchange the con-
stant part of the antibodies. The different constant parts are called isotypes. These isotypes have distinct 
functions	within	the	immune	system	due	to	their	binding	affinity	to	cell	surface	receptors	recognizing	
the constant part of the heavy chain (Fc-receptors), different activation of the complement system and 
due to varying accessibility to different compartments (Table 1). Poltooralsky et. al established the 
basic	principles	of	class	switch	recombination	model	in	2000	105-107. During the B cell development 
the DNA recombination is a complex and fragile event that has to be carefully controlled by the cells 
to avoid translocation mistakes, which can lead to malignant transformations. One of the most com-
mon translocation mistakes is the translocation of the oncogene c-myc under the Igh promoter. This 
translocation is often responsible for B cell lymphomas . The main enzyme involved for the malignant 
transformation in B cells is activation-induced cytidine deaminase (AID)108-110. 
The CSR mechanism is based on an intrachromosomal deletion recombination between switch (S) 
regions that are located 5` of the heavy chain constant region sequence (Figure 9). These regions have 
a	special	nucleotide	motive	containing	20-80	bp	Guanine	(G)-rich	tandem	repeats	on	the	nontranslated	
DNA	strand.	The	recombination	site	between	the	two	S	regions	is	very	flexible	and	occurs	near	or	with-
in the S region111-113. CSR is induced via	activation	of	B	cells	by	cytokines	such	as	interferon-(IFN)-γ,	
interleukine	(Il)-4	or	transforming	growth	factor-(TGF)-β	and	in	the	case	of	T	cell	independent	class	
switch (TI) via	Toll-like	receptors	(TLR)	101,102. These activation signals lead to the expression of AID 
by	regulatory	factors	like	paired	box	protein	5	(PAX5),	E-box	proteins	114,	homeobox	C4	(HOXC4)	
115, interferon regulatory factor (IRF)-4 116	and	fork	head	box	O1	(FOXO1)	117. AID deaminates deoxy 
Cytidine to deoxyuracil (dU) together with the protein 14-3-3 118-124. The protein 14-3-3 is important 
for the recruitment of AID to the donor and acceptor S region. The recruitment is achieved via the spe-
cific	binding	of	the	protein	14-3-3	to	the	repetitive	S	region	motive	5’-AGCT-3	124. The deamination 
of the deoxycytidine activates the base excision repair enzyme uracil DNA glycosylase (UNG), which 
removes the dU residues and introduces a SSB 125,126. 
Sequentially	after	the	action	of	UNG	the	apurinic/apyrimidinic	endonuclease	APE1/2	nicks	the	DNA	
a second time and introduces double strand breaks (DSBs) 127. These DSBs are then ligated via the 
ubiquitous	non-homologous	end-joining	(NHEJ)	DNA	repair	machinery	composed	of	Ku70,	Ku80	and	
XRCC4-ligaseIV	to	the	acceptor	S	region	45,128-130. 
Class switch recombination:
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A) Represents the already recombined variable region (pink box) followed by a nicked switch S 
region and the sequence for the Ig isotype constant regions Cµ (coding for IgM) and Cδ (coding 
for IgD), which are expressed simultaneously in the cell until the first CSR. These are indicated 
by the two mRNAs µ and δ (red line). The other isotype constant parts are located 3’ from Cδ with 
the corresponding S regions 5’ from the corresponding constant region. B) shows the recombi-
nation of the two nicked S regions after the variable region (VDJ) and before the Cα. Now a DDS 
break is introduced and the DNA is religated. C) the new immune globulin isotype is expressed. 
Adapted from104 
Figure 9: The distribution of the different constant region isotype classes for the human IgH  
      on the chromosome 14
Finally the B cell changed the isotype of the BCR but not the avidity of the variable region. The way 
how a B cell decides, which isotype switch it has to perform is still not known. There is evidences that 
during the GC reaction the cells receive certain stimuli to switch to the right isotype 131. This will be 
explained in more detail in the next chapter.
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The Germinal center reaction:
 
Walther	Flemming	first	 described	 the	GC	 in	1884	 as	 a	 very	dense	 and	hyperproliferative	 area.	He	
speculated that the lymphopoiesis occurs in these regions. In fact the GC is a microanatomical struc-
ture in secondary lymphoid organs where the adaptive B lymphocytes are selected for recognition of 
a	specific	antigen,	while	retaining	self-tolerance.	The	maturation	of	 the	adaptive	 immune	system	is	
highly dependent on the reactions taking place in the secondary lymphoid organs. A complex interac-
tion with stromal cells, dendritic cells (DC), macrophages and antigens support the development of 
antigen	specific	B	and	T	cells	(Figure	10).	Naïve	T	cells	develop	to	memory	T	cells,	effector	T	cells	
and TFH.	Antigen-specific	activated	mature	naïve	B	cells	acquire	a	memory	B	cell	phenotype,	affinity	
mature the BCR via somatic hyper mutation and eventually switch to different isotypes and further 
develop	into	antibody	secreting	plasmablasts	and/or	plasma	cells.	The	major	part	of	B	cell	develop-
ment in the secondary lymphoid organs happens in the GC reaction. A GC follicle is a structure that 
is	stable	for	more	than	3	weeks	where	B	cells	undergo	several	rounds	of	selection,	affinity	maturation	
and	proliferation	(Figure	12).	Antigen-specific	memory	B	cells	are	able	to	enter	the	GC	reaction	more	
than once. Especially after an antigen recall second GC reaction can be formed 132,133 (Figure 12D). 
 It is very characteristic for class switched B cells that they can only reach the memory compartment 
after interacting with TFH cells (Figure 12). TFH cells have the only sole purpose of checking indirectly 
the	BCR	for	its	antigen	specificity.	The	whole	anatomical	structure	of	secondary	lymphoid	organs	is	
made for capturing, concentrating and presenting antigens to support proliferation and selection of 
the adaptive immune system (Figure 11). This is why the GCs are located in the secondary lymphoid 
organs	namely	spleen,	Peyer’s	patches,	tonsils	and	lymph	nodes,	where	the	chances	to	encounter	anti-
gens and pathogen is the highest. In this section the focus will be on the GC in lymph nodes.
The	 lymph	 node	 is	 a	 secondary	 lymphoid	 organ	with	 a	 fibrous	 capsule,	 which	 connects	 the	 lym-
phatic system and the blood stream. The capsule has afferent lymph vessels where the inter-
stitial	 fluid	 enters	 the	 lymph	 node	 and	 efferent	 vessels	 to	 drain	 the	 lymph	 node	 (Figure	 10A).	
The inner part of the capsule where the afferent lymph vessels enter the lymph node is called 
the subcapsular sinus. The area where the blood enters and leaves together with the effer-
ent lymph vessels is called medulla. These two regions contain two types of macrophages. 
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The	 first	 type	 is	 located	 at	 the	 afferent	 part	 of	 the	 lymphatic	 vessel	 and	 called	 the	 
subcapsular sinus macrophages (CD169+ CD11clo CD11b+) (SSMs) or (SCSs). 
In the medulla the medullary macrophages (SIGN-R1+ F4/80+) (MMs) are located 135-137	(Figure	10).	 
The SSM protect the lymph node from direct contact to pathogens and support the antigen sampling 
in the afferent lymph 134. The two different macrophages vary in their endocytic activity and the lyso-
somal degradation of pathogens 134. SSMs retain the pathogens much longer on the surface than MMs 
and have a less mature phenotype 135,136,138. This properties of SSMs might be important for retain-
ing the antigens longer in the lymph node therefore allowing its presentation to B cells much longer, 
which will be important for the distribution of the antigen through the B cells in the antigen transport 
part (Figure 11) 134. In general the two macrophages are important to protect the host from systemic 
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A) Illustrates the different microanatomical structures of a lymph node in blue the T cell zone, 
in yellow the B cell zone, in grey the subcapsular sinus together with the afferent and effer-
ent lymphatic vessels, in green the subcapsular macrophages and in brown the medulla. 
B) shows the follicular conduit where fibroblastic reticular cells (FRCs) and the follicular den-
dritic cells (FDCs) are attached to the collagen fibers of the conduit. Close to the paracorti-
cal conduit the dendritic cells are located. The B cells and T cells move along the conduits, 
which have the corresponding chemokines bound. Blue dots stand for the B cell chemokine 
CXCL13 and in red and brown the T cell chemokines CCL21 and CCL19, respectively. 
Figure adapted from 141,187
Figure 10 The anatomy of a Lymph node
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distribution of pathogens 139,140.
Below	 the	 subcapsular	 sinus	 the	 lymph	 node	 is	 filled	 with	 fibroblastic	 reticular	 cells	 (FRCs)	 of	
two different types: the follicular conduits (B cell zone), the paracortical conduits (T cell zone) 
and	 marginal	 reticular	 cells	 (MRCs)	 (Figure	 10B)	 134. These cells are important to provide the 
A) 1. After a B cell enters the lymph node through a high epithelial venule the chemokine 
receptor CXCR5 attracts the B cell along the CXCL13 gradient to the B cell follicle. 2. In the 
B cell zone the cell moves along the conduit and expresses the EBI2 receptor. The EBI2 
receptor attracts the B cell to the supcapsular sinus where the EBI2L ligand is present at 
highest concentration. 3. The cell down-regulates the EBI2 receptor and moves away from 
the subcapsular sinus, loaded with immune complexes either on the CD21 or the BCR recep-
tor. 4. The cell strolls back to the center. On the way to the center of the B cell zone the cell 
looses the previously CD21-bound antigen to FDCs and upregulates the chemokine receptor 
CXCR7. 5. Finally, the B cell leaves the lymph node via the Sphingosine 1 phosphate (S1P) 
signal. The figure is adapted from 143: B) 6. The binding of complemen-bound immune com-
plex (IC) to the complement receptor 3 CR3 on the SSMs. The IC is then shuttled to the in-
ner site of the subcabsular sinus. 7. The B cell interacts with the complement receptor CD21 
and the bound IC in the SSM. 8. The IC detaches from the SSM. The IC-loaded B cell moves 
through the follicle and deposits the IC on FDCs. 9. An alternative to the CD21 binding of the 
IC is the binding via the FcR. 10. An antigen specific B cell captures a small soluble antigen 
from the conduit. The figure is adapted from 134
Figure 11: The movement and antigen interaction of the B cell in the lymph node
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infrastructure and to guide the B and T cells between the different microanatomical structures. 
The	 FRCs	 produce	 type	 1	 collagen	 fibers	 which	 are	 called	 conduits.	 The	 collagen	 
fibers,	form	a	robe-like	structure	of	1-2	μm	in	diameter,	where	B	and	T	cells	can	crawl	along	141,142.
Near the conduits the follicular dendritic cells (FDCs) and FRCs produce chemokine gradients, which 
guide B and T cells along the conduits to different locations in the lymph node. The FRCs of the fol-
licular	conduits	produce	a	chemokine	gradient	of	CXCL13	together	with	MRCs	to	attract	the	B	cells	
towards	the	subcapsular	sinus	region	(Figure		10B	and	11)	134. 
Interestingly,	the	chemokine	CXCL13	has	a	high	affinity	to	collagen	fibers	and	concentrates	along	the	
collagen	fibers,	which	facilitates	the	movement	of	the	B	cells144.	Furthermore	the	CXCL13	production	
is	highly	dependent	on	the	lymphotoxin-α1β2	production	of	B	cells,	which	leads	to	a	positive	feedback	
loop and increasing the production of both chemokines 145. FRCs and FDCs in the paracortical con-
duits	transport	CCL19	and	CCL21	to	guide	T	cells	and	dendritic	cells	along	the	collagen	fibers	to	the	
paracortical region 146-149.	This	is	where	the	naïve	CD4	T	cells	develop	to	effector,	memory	and	TFH by 
encountering the processed antigen as a peptide on the MHC II of dendritic cells 150. The T cells with 
the	highest	TCR-binding	affinity	to	the	bound	peptide	on	MHC	class	II	receive	a	signal	to	up-regulate	
CXCR5	and	subsequently	enter	the	TFH maturation pathway 
151. The pre-GC TFH	cell	waits	at	the	T/B	
zone	interphase	until	an	activated	naïve	B	cell	with	the	affinity	for	the	corresponding	antigen	arrives	
(Figure 12A). Together the cells start to form the immune synapse 155. The scanning of activated B 
cells	in	the	T/B	interphase	by	the	TFH cells is important to reduce auto-reactivity of memory B cells. 
Several	 studies	could	show	that	autoreactive	B	cells	are	enriched	 in	 the	T/B	 interphase	zone	 152-154. 
 
The immune synapse has a bilateral effect, B and T cells receive co-stimulatory signals together with 
cytokine signals, which lead to further maturation of the TFH and B cells 
156. The B cells either mature 
into short-lived plasma cells or follicular B cells, which then end up as GC B cells (Figure 12B) 157.
During the immune synapse formation the TFH screens the peptide-loaded MHC-class-
II molecules on the B cells for the right peptide. Peptide recognition induces a posi-
tive feedback signaling, which induces the upregulation of co-stimulatory molecules 
such	 as	 CD40L/CD40106,158,159,	 (CD80/CD86)/CTLA-4160,	 OX40/OX40L161,	 ICOS/ICOSL162. 
TFH-derived	IL-21	and	ICOS/ICOSL	interaction	induce	expression	of	the	factor	B	cell	 lymphoma	6	
(Bcl-6) in both cells, which is important for TFH and B cells maturation to form the GC reaction 
163-166 
(Figure 12B). 
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Alternatively, B cells start to express B lymphocyte-induced maturation protein 1 
(BLIMP-1	 or	 PRDM1),	 which	 leads	 to	 short-lived	 plasma	 cell	 differentiation	 with-
out GC formation and no SHM but eventually with CSR in the extrafollicular space 167. 
Furthermore	IL-21	induces	the	proliferation	of		B	cells	168 (Figure 12A and B), which is very impor-
tant to fuel the GC with enough B cells before the SHM starts 169. Before the initiation of GC reaction, 
proliferating B cells start to form the secondary follicle composed of Bcl-6-positive B cells, FDCs and 
TFH  cells  (Figure 12B) 
157.  After the secondary follicle is formed, it starts to polarize into a light zone 
containing	antigen-loaded	FDCs	together	with	antigen-scific	GC-TFH and a dark zone with proliferating 
B cells 170.	Now	the	GC	reaction	starts	and	high	affinity	class	switch	memory	B	cells	and	plasma	cells	are	 
generated (Figure 12C and D).
A) Antigen activated B cell leave the B cell zone and processes the antigen for further pres-
entation to the antigen specific TFH cell at the border of T and B cell zone. During the B/T cell 
interaction of the pre-GC TFH cell releases Il-21 and mature to a GC-TFH cell by Bcl-6 expres-
sion. B) The Bcl-6 B cell starts to proliferate and form the secondary follicle while BLIMP-1 
B cell develops to short lived plasma cells in the extra follicular space. C) The Bcl-6 B cells 
polarize and divide the follicle into a hyper-proliferative dark zone that contains centroblasts 
and a light zone with activated follicular dendritic cells (FDC), a few B cells which are here 
called centrocytes and GC TFH. This polarization induces the GC reaction D) After antigen 
re-challenge the already mature memory B cell pool can start to form a secondary GC reac-
tion and further mature and produce new variants of memory and plasma cells. The figure 
was adapted from 157
Figure 12: Induction of a GC reaction
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The last step in the development of B cells is the stage when all the checkpoints are passed and 
the cells turn into a highly productive antibody-secreting phenotype. This state of maturity is 
called plasma cells. B cells have two developmental routes to enter the plasma cell compartment. 
The	first	 one	 is	 the	 extra-follicular	 route	 (MZ	 in	 the	 spleen	 and	T/B	 cell	 border	 in	 lymph	 nodes),	
which is less controlled than the intra-follicular pathway. In the extra-follicular space B cells mature 
to	 plasma	 cells	 due	 to	 relatively	 high	 affinity	 of	 the	BCR	 for	 an	 antigen	 and	 generate	 short-lived	 
plasma cells 171. This fast response is important to generate the early response against pathogens. Since 
the short-lived plasma cells are less controlled by checkpoints the secreted antibodies might be cross-
reactive (Figure 12 and 8) 75. To protect the organism from autoreactive antibodies the cells will only 
survive for 3 days. In contrast to the extra-follicular pathway the intra-follicular differentiation pro-
duces	long-lived	plasma	cells,	which	secrete	high-affinity	CSR	antibodies	157.	The	BLIMP-1	express-
ing	plasma	cells	up-regulate	the	chemokine	receptor	CXCR4	and	migrate	to	the	bone	marrow	where	
the cells searche for a niche between the stromal cells.
The principle mechanism for the maturation of short-or long-lived plasma cells is similar. Due to 
IL-21	stimulation	B	cells	start	to	up-regulate	the	expression	of	interferon	regulatory	factor	4	(IRF4).	
The	amount	of	IRF4	expression	influences	the	expression	level	of	different	proteins	like	AID	116 and 
at	high	levels	IRF4	induces	the	expression	of	BLIMP-1	172. Blimp-1 is the master switch regulator for 
plasma	cell	differentiation,	which	sequentially	downregulates	the	Bcl-6,	AID	and	the	PAX5	expres-
sion 173-175.	A	negative	feedback	loop	of	BLIMP-1	changes	the	fate	of	the	cells	towards	the	plasmab-
last/plasma	cell	lineage	and	upregulates	the	X-box-binding	protein-1	(Xbp-1)	176.	Xbp-1	is	necessary	
to handle the high amount of antibody that plasma cells produce, which leads to an increase of the 
unfolded protein response. 
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Anti-MAG neuropathy
Anti-MAG neuropathy is an autoimmune disease, which is characterized by IgM antibodies recog-
nizing myelin-associated glycoprotein (MAG), which is a component of the nervous system 177,178. In 
anti-MAG neuropathy patients the production of anti-MAG IgM antibodies is associated with an IgM-
monoclonal	gammopathy	of	unknown	significance		(MGUS)	179.	IgM-MGUS	is	defined	by	a	serum	
concentration	of	a	monoclonal	IgM	<30g/l,	the	amount	of	clonal	plasma	cells	in	the	bone	marrow	is	
less	than	10%	and	the	absence	of	end-organ	damage	due	to	plasma	cell	proliferation	180. An important 
criterion is the absence of any evidence of multiple myeloma, macroglobulinemia, amyloidosis or 
similar plasma cell proliferative disorders 181. In general, MGUS does not necessary involve a malig-
nancy.	The	incidence	of	monoclonal	gammopathy	is	increasing	in	aging	humans	with	3%	in	patients	
>70	years	182	and	10%	in	individuals	>80	years	183. 
The	risk	for	a	MGUS	carrier	to	develop	a	malignant	stage	is	1%	per	year	180. Predominantly males 
between	the	ages	of	40-70	years	are	affected	by	anti-MAG	neuropathy	181,184. 
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A) Illustrates an axon wrapped with myelin sheaths from Schwann cells. B) Electron 
microscopy picture of anti-MAG neuropathy biopsy with IgM kappa paraprotein deposits in the 
myelin sheath. The figure is adapted from 180
Figure 13: IgM deposits between the myelin sheath
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MAG is expressed on myelin-producing cells like Schwann cells in the peripheral nervous sys-
tem (PNS) and on oligodendrocytes in the central nervous system (CNS) (Figure 13A). Due to the 
binding of the IgM antibody to MAG, the antibody forms aggregates and induces a widening of the 
myelin sheath (Figure 13B)185	or	 leads	to	inflammation,	demyelination	and	axonal	degeneration	via 
activation of the complement system (Figure 14B). The damage to the myelin sheaths around the 
axon reduces the nerve conductivity and slows down the transmission of nerve impulses 180 (Fig-
ure	 13).	 This	 leads	 to	 reduced	 sensory	 and	motor	 function	 in	 the	 PNS	 and	 beginning	 first	 in	 the	
distal extremities and later extending to proximal extremities. Usually the symptoms start in the 
toes and spread to the feet and legs. The symptoms resulting from the loss of nerve conductivity 
usually progress symmetrically and include primarily sensory loss, paraesthesia, loss of vibration 
sense and proprioception, subsequently leading to sensory ataxia, muscle weakness, tremor of the hand 
and	areflexia.	The	disease	course	 is	slowly	progressive	over	some	months	 to	several	years	 180,181,184. 
The diagnosis of the disease is accomplished by electroephysiology of the PNS, histology of nerve 
fibers,	serum	IgM	anti-MAG	antibody	titer,	free	light	chains	in	the	urine	and	serum	protein	electropho-
resis for the monoclonal IgM paraprotein 180,186.
Tested therapies for the anti-MAG neuropathy are plasma exchange, intravenous immunoglobulin 
application	 (IVIG),	 chlorambucil,	 cyclophosphamide,	fludarabine,	 cladribine,	 interferone-alpha	 and	
autologous	bone	marrow	transplantation.	Unfortunately,	all	of	these	therapies	do	not	lead	to	a	scinifi-
cant	benefit	for	the	patients	180,187. The lack of therapeutic agents led to the idea of using Rituximab, 
which	 is	 a	 chimeric	monoclonal	 antibody	 against	CD20.	CD20	 is	 a	 pan	B	 cell	marker	 and	Ritux-
imab	 depletes	B	 cells	 in	 the	 periphery	 (Figure	 14A).	The	 clinical	 efficacy	 and	 safety	 of	 this	 anti-
body is now in clinical trial phase 3 (RIMAG	study	http://clinicaltrials.gov/ct2/show/NCT00259974) 
for Anti-MAG neuropathy.
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Rituximab
Rituximab	is	the	first	therapeutic	monoclonal	antibody	(mAb),	which	was	approved	by	the	food	and	drug	
administration (FDA) in the USA for the treatment of B cell lymphomas 188 and later on for the autoimmune 
disease RA. More recently, Rituximab received FDA approval for the treatment of patients with granulo-
matosis	with	polyangiitis	(Wegener’s	granulomatosis)	and	microscopic	polyangiitis.	Today	it	is	often	used	
in	off-label	studies,	for	other	autoimmune	diseases	like,	SLE,	idiopathic	thrombocytopenic	purpura,	my-
asthenia	gravis,	inflammatory	neuropathies,	multiple	sclerosis	and	in	this	case	anti-MAG	neuropathy	189. 
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Figure is adapted from 191
Figure 14: Pan B cell markers and the action of Rituximab
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The	 suffix	 stem	 -xi	 indicates	 that	 Rituximab	 is	 a	 chimeric	 antibody	 derived	 from	 an	 anti-human	
CD20	mouse	mAb	 and	 genetically	 engineered	 on	 the	 basis	 of	 the	 sequence	 of	 a	 human	 constant	 
region 190.	CD20	is	a	pan	B	cell	marker,	which	is	expressed	on	immature	and	mature	B	lymphocytes	
and lost upon plasma cell differentiation 189 (Figure 14). 
The human constant part used in this particular mAb is IgG1, which is able to eliminate antibody target 
cells in the blood (Table 2). A single course of Rituximab leads to depletion of B cells from peripheral 
blood for 6–12 months 189.	IgG1	has	two	major	pathways	to	deplete	cells	(see	table	1).	The	first	path-
way is the complement-dependent-cytotoxicity (CDC) 192.	Rituximab	binds	and	redistributes	CD20	to	
lipid rafts allowing antibody clustering 193. Subsequently, C1q binds to the constant part of the clustered 
antibodies	and	initiates	the	complement	cascade	that	finally	lyses	the	target	cells	(Figure	14	B)	194,195. 
The second mechanism is the antibody-depended cell-mediated cytotoxicity (ADCC). During ADCC 
the	antigen-bound	antibodies	on	the	target	cells	binds	to	activating	FcγR	on	myeloid	cells	in	particular	
monocytes/macrophages	and	lymphoid	NK	cells.	The	binding	of	the	antigen-bound	antibodies	to	the	
FcγR	activates	the	NK	cells	and	induces	cell	death	of	the	target	cells	(Figure	14	C)	2. It is still under 
debate,	which	of	 the	 two	pathways	 is	 the	more	 important	for	Rituximab	efficacy.	In	certain	studies	
Rituximab	showed	less	efficacy	due	to	a	FcγR	polymorphism,	which	reduces	the	binding	affinity	of	the	
Fc-part of the mAb to the receptor 196-199. These studies underline the strong ADCC component for the 
B cell depletion of Rituximab.
Since	the	first	generation	of	anti-CD20	antibody	showed	a	high	efficacy	in	depleting	B	cells,	while	
still some patients are not responding to it the search for better mAb is ongoing. Nowadays the third 
generation	of	anti-CD20	antibodies	is	in	the	last	step	of	the	clinical	phase	III	study.	The	novelties	of	
these antibodies are that their variable region is fully human and the Fc domain is mutated to enhance 
the	binding	 affinity	 to	 the	FcγR.	These	 improvements	 should	 reduce	 the	 side	 effects	 of	Rituximab	 
treatment as an immune reaction towards the murine parts of the antibody can develop and enhanced 
FcγR	binding	should	enhance	ADCC	dependent	depletion	200.  
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The rationale for B cell-depleting therapies in autoimmune diseases has been the concept that immune 
depletion could eliminate autoreactive B lymphocytes and that a de novo regeneration of B cell memo-
ry	from	pro-B	cell	precursors	-	which	do	not	express	CD20	-	could	reestablish	tolerance.	However,	no	
study	has	demonstrated	that	B	cell-depleting	therapies	can	actually	reconfigure	B	cell	memory	through	
detection	of	phenotypic	or	functional	renewal	of	the	B	cell	repertoire.	Thus,	despite	its	clinical	efficacy	
and widespread use, the mechanisms whereby Rituximab treatment confers its long-term clinical ef-
ficacy	in	patients	with	autoimmune	diseases	are	unclear	201. 
Anti-MAG	 neuropathy	 is	 a	well-defined	 antibody-mediated	 disease	 of	 the	 peripheral	 nervous	 sys-
tem, which develops in individuals with an IgM monoclonal gammopathy of unknown sig-
nificance	 (MGUS)	 and	 is	 characterized	 by	 autoreactivity	 towards	 MAG,	 a	 protein	 expressed	 in	
the peripheral myelin sheaths. IgM anti-MAG antibodies, which are consistently detectable in 
these patients are very likely pathogenic since their adoptive transfer to susceptible host ani-
mals induces peripheral demyelination and symptoms resembling these observed in patients with 
anti-MAG neuropathy202-205. Thus, anti-MAG neuropathy stands out among other human 
autoimmune diseases due to the known identity of the target antigen and a clear 
disease-association with IgM autoantibodies. Most available immunomodulatory treatments offer 
only	transient	benefits	to	some	patients	with	anti-MAG	neuropathy,	whereas	most	remain	treatment-
resistant 185. A recent randomized controlled clinical trial demonstrated that Rituximab is, so far, the 
most	effective	therapeutic	agent	providing	long-term	benefits	to	a	subset	of	these	patients206. To un-
derstand	whether	these	beneficial	effects	are	mediated	by	lymphodepletion	alone	or	are	sustained	by	
a newly developed peripheral B cell compartment we examined the Ig gene repertoire in patients 
with anti-MAG neuropathy during Rituximab therapy. To get more insight into the B cell compart-
ment we used single-cell PCR, which has a very high resolution for the different BCR recombina-
tions in different B cell compartments. In this study we analyzed three different B cell compartment 
before	 and	 one	 year	 after	 Rituximab	 therapy,	 namely	mature	 naïve	 B	 cells	 (CD19+ CD27- IgM+), 
IgM memory B cells (CD19+ CD27+ IgM+) and IgG memory B cells (CD19+ CD27- IgG+). These three 
compartments are the main populations in the blood and IgM memory B cells are suspected to be in-
volved in this disease.
The aim of the study
35
Results
To	determine	whether	Rituximab-mediated	B	cell	depletion	leads	to	significant	changes	in	the	periph-
eral	Ig	gene	repertoire,	we	amplified	and	sequenced	Ig	heavy	chain	genes	(IgH)	of	single-sorted	naïve,	
IgM memory and IgG memory B cells before and 12 months after therapy. Samples were obtained 
during a placebo-controlled clinical trial of Rituximab in patients with anti-MAG neuropathy, during 
which	patients	were	 randomized	 to	 four	weekly	 infusions	 of	 375mg/m3 Rituximab or placebo, i.e. 
normal saline solution 206.	The	first	point	we	addressed	was	the	recombination	of	the	antibody	heavy	
chain in different B cell compartments. For this we blasted the single cell PCR-derived IgH sequences 
against germline sequences and compared the different VH, DH and JH gene segments in amount and 
percent of usage. As controls we used age-matched healthy controls (Figure 15). To avoid a bias of 
the	analytical	bias	due	to	PCR	amplification	efficiency	we	calculated	the	percentage	of	total	derived	
sequences form all the patients. Single patients are depicted in Figure 16, 17 and 18.
Ig gene repertoire analysis during therapeutic B cell depletion
Next page: IgH chain gene variable (V) region (Figure 1A), diversity (D) region 
(Figure 1B), and joining (J) regions (Figure 1C) repertoires in single-cell sorted CD19+CD27-
IgM+, CD19+CD27+IgM+ and CD19+CD27+IgG+ B cells, respectively. Samples were analyzed 
before and 12 months after Rituximab, placebo (normal saline solution) therapy and age-
matched healthy controls. Clonally expanded sequences were counted as one sequence. The 
numbers in circles indicate the number of individual sequences per patient cohort and per 
time point that were analyzed. Data for each individual donor are provided in Figure 17-19. 
The two-tailed Fisher’s exact test was used to evaluate VH, DH, and JH repertoires.
Figure 15: Ig gene repertoire analysis in patients with anti-MAG neuropathy before and 12  
        months after Rituximab-mediated B cell depletion
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Page 39: IgH chain gene variable (VH) repertoires in single-cell sorted CD19+CD27-IgM+, 
CD19+CD27-IgM+ and CD19+CD27+IgG+ B cells, respectively. Samples were analyzed be-
fore and 12 months after Rituximab and placebo (normal saline solution) therapy. Clonally 
expanded sequences were counted as one sequence. The numbers in circles indicate the 
number of individual sequences per patient. 
Page 40: IgH diversity (DH) region repertoires in single-cell sorted CD19+CD27-IgM+, 
CD19+CD27-IgM+ and CD19+CD27+IgG+ B cells, respectively. Samples were analyzed 
before and 12 months after Rituximab and placebo (normal saline solution) therapy. Clonally 
expanded sequences were counted as one sequence. The numbers in circles indicate the 
number of individual sequences per patient.
Page 41: IgH chain joining (JH) regions repertoires in single-cell sorted CD19+CD27-IgM+, 
CD19+CD27-IgM+ and CD19+CD27+IgG+ B cells, respectively. Samples were analyzed be-
fore and 12 months after Rituximab and placebo (normal saline solution) therapy. Clonally 
expanded sequences were counted as one sequence. The numbers in circles indicate the 
number of individual sequences per patient.
Figure 16: Single patient VH elements analysis of anti-MAG neuropathy patients before and  
       12 month after Rituximab treatment
Figure 17: Single patient DH elements analysis of anti-MAG neuropathy patients before and  
       12 month after Rituximab treatment
Figure 18: Single patient JH elements analysis of anti-MAG neuropathy patients before and  
       12 month after Rituximab treatment
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The VH, DH and JH gene family usage before treatment initiation did not differ between 
these two subgroups and was similar to demographically age-matched healthy blood donors 
(Figure 15). VH3, the largest variable region family was found most frequently in any of the B cell sub-
sets, followed by VH4 and VH1. B cell reconstitution 12 months after Rituximab treatment did not sig-
nificantly	alter	the	VH, DH and JH	gene	repertoire	in	circulating	naïve-,	IgM	memory-	and	IgG	memory	
B cells. Additionally, we could not observe an increase of VH3	usage	comparing	the	mature	naïve	B	cell	
with the IgM memory B cells, which was reported by Tsuiji et al. 86
  
Next, we examined IgH chain characteristics such as the length, isoelectric point of the IgH 
complementarity-determining region 3 (CDR3), which have previously been associated with antibody-
mediated autoreactivity 12,62. The analysis of a large number of sequences enabled us to detect small dif-
ferences	such	as	a	modest	increase	in	IgH	CDR3	lengths	in	naïve	and	IgM-expressing	memory	B	cells	
from Rituximab-treated patients, whereas isoelectric points remained unchanged following peripheral 
B cell reconstitution comparing the individual B cell linages before and after the therapy (Figure 19). 
We conclude that there are no consistent abnormalities in the IgH chain repertoires in patients with 
anti-MAG	neuropathy	and	that	Rituximab-mediated	peripheral	B	cell	depletion	does	not	significantly	
change the VH, DH and JH	gene	family	usage	of	naïve	and	memory	B	cells.	
Size	and	antigen-specificities	of	IgM	memory	B	cell	expansions	in	 
anti-MAG neuropathy
Patients with anti-MAG neuropathy showed substantial clonal and oligoclonal expansions within the 
IgM	memory	B	cell	 compartment	before	 treatment	 initiation:	21.5%	of	809	analyzed	 single-sorted	
cells	had	identical	IgH	CDR3	gene	sequences	compared	to	2.3%	of	574	sequences	derived	from	IgG	
memory	B	cells	(p	<	0.0001)	(Figure	20A).	The	size	of	clonal	IgM	memory	B	cell	expansions	was	
markedly	reduced	following	Rituximab	therapy	but	not	in	placebo-treated	patients	(Figure	20B).	
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The same number of individual Igh chain gene sequences as in Figure 1 were analyzed and 
the results are displayed as data derived from individual sequences. The first row shows 
the length of the CDR3 for the placebo treated (left panel) and Rituximab treated patients 
(right panel). The lower graphs show the isoelectric points of the CDR3 for placebo and 
treated patients. Data points represent individual sequences. Horizontal bars and error bars 
indicate mean ± standard error mean (SEM). The unpaired student t-test was used to evalu-
ate CDR3 lengths and isoelectric points.
Figure 19: CDR3 length and CDR3 isoelectric points before and after Rituximab therapy
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Before therapyA
IgM IgG IgM IgG
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After Rituximab therapy
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expanded sequencesnon expanded sequences
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653 325 156 221
325
Frequency of clonally expanded IgM memory B cells in patients with anti-MAG neuropathy 
before and after Rituximab therapy as compared to the IgG memory compartment. Before 
therapy, data from all study subjects were included. Post-treatment data are referring to those 
patients that received Rituximab therapy. The numbers in circles indicate the number of in-
dividual sequences per patient cohort and per time point that were analyzed. B IgM memory 
B cell clonal expansions before and after therapy in placebo-treated patients compared to 
Rituximab treated patients.  Results are based on the analysis of individual sequences in 
both clinical subgroups. The two-tailed Fisher’s exact test was used to compare proportions 
of clonal expansions.
We detected a few expanded clones in the CD19+CD27-IgM+ compartment: in placebo-treated pa-
tients	0%	of	a	total	of	207	sequences	before	and	3%	of	170	sequences	after	therapy,	in	Rituximab-
treated	patients	0.3%	of	539	sequences	before	and	1.4%	of	353	sequences	after	 therapy.	These	ex-
pansions but not non-expanded sequences were somatically hypermutated suggesting that these 
clones represent post-GC B cells. In our opinion, the most likely explanation for the presence 
of these few expanded and somatically hypermutated sequences are CD27- memory B cells that 
occur at low frequencies in the blood of healthy individuals and patients with autoimmune diseases 207. 
Figure 20: Comparing the size of IgM memory and IgG memory expansions before 
        and after Rituximab treatment:
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The overall size of these expansions was minimal in comparison to the size of expanded sequences 
within the CD19+CD27+IgM+	compartment	(Figure	20).	We	observed	that	the	frequency	of	expanded	
IgG memory B cells increased over time in placebo-treated patients.  However, Rituximab therapy had 
only a small effect on the size of clonally related IgG memory B cells (Figure 21). Compared to the 
placebo treated patients the expansion is minor.
Placebo
before after
P=0.0005
120 140
before after
Rituximab treated patients
P=0.021
451 225
Comparison of the frequency of clonally expanded IgG memory B cell before and after thera-
py in placebo-treated patients and Rituximab treated patients. The numbers in circles indicate 
the number of individual sequences per patient cohort and per time point that were analyzed. 
The two-tailed Fisher’s exact test was used to compare proportions of clonal expansions.
Since anti-MAG neuropathy is an IgM mediated disease we determine whether expanded IgM memory 
B cell clones recognize MAG. For this we re-sorted IgM memory B cells isolated before treatment 
initiation	and	amplified	full-length	IgH	and	IgL	chain	variable	region	gene	transcripts	derived	from	
highly	expanded	sequences	by	RT-PCR.	Amplified	products	were	cloned	into	eukaryotic	expression	
vectors	to	produce	monoclonal	IgG	antibodies	with	antigen	specificities	identical	to	the	initial	B	cell	
antigen receptors 208. The antigenic determinant of MAG resides in the carbohydrate component of the 
molecule,	as	demonstrated	by	the	loss	of	reactivity	following	deglycosylation	of	purified	human	MAG	
209. A similar carbohydrate structure is found in the ganglioside fraction of the human peripheral nerve 
and	has	been	identified	as	sulfoglucuronyl	glycosphingolipid	(SGPG),	an	acidic	glycolipid	exclusively	
expressed in the peripheral nervous system 210. Pathogenic IgM antibodies in patients with MAG neu-
Figure 21: The size of the IgG memory B cell expansions in placebo  
        and Rituximab treated patients: 
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ropathy	may	recognize	both	MAG	and	SGPG,	although	the	avidity	for	SGPG	is	reported	to	be	10-100	
fold lower compared to MAG 211.	Therefore,	we	tested	both	specificities	in	comparison	to	an	irrelevant	
control protein, a prominent B cell antigen of the ubiquitous gamma herpesvirus Epstein-Barr virus 
(EBV), i.e. the EBV nuclear antigen 1 (Figure 22)
All of the 5 clones optained from blood IgM memory B cell expansions before therapy recognized 
MAG	purified	from	human	myelin	in	a	concentration-dependent	manner.	One	out	of	these	5	clones	
showed a strong cross-reactivity towards SGPG (Figure 22). Non-expanded IgM memory clones nei-
ther recognized MAG nor SGPG (Figure 22). Moreover, we did not observe any binding to EBNA1 
(Figure 22) indicating that IgM memory B cell expansions in patients with MAG-neuropathy recog-
nize the target antigen of the disease. The sequences of the 5 expanded antibody clones are derived 
from different germline VH elements and show some similarity in the amino acid content (Figure 23). 
The sequences homologies are manly located in the framework regions. The CDRs do only show minor 
conservations. In CDR1 the phenylalanine (F) in all the clones and in CDR2 isoleucine is conserved 
in 3 out of 5 expanded antibody clones namely P5 and P11. The CDR3 do not show any homology 
between	the	different	heavy	chains.	P27	shows	the	highest	amino	acid	exchange	85.25%	compared	to	
other	at	around	91%.
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Page 48: Specificity of IgM memory B cell expansions as assessed by ELISA. Recombinant 
antibodies expressed from highly expanded sequences, which are highlighted as circles in 
Figure 23, were tested for binding to purified MAG protein, to SGPG, an acidic glycolipid 
exclusively expressed in the peripheral nervous system towards which cross-reactivity of 
anti-MAG antibodies is described, and to EBNA1, an immunodominant protein expressed 
by the ubiquitous γ-herpesvirus EBV. OD-values from the positive control provided by the 
manufacturer, a secondary antibody control, an antibody (hu-8-18C5) that recognizes myelin 
oligodendrocyte glycoprotein (MOG) to control for antigen specificity and recombinantly ex-
pressed antibodies from patients with anti-MAG neuropathy are shown.
Figure 22: Anti-MAG ELISA of 5 expanded and 2 non-expanded IgM memory B cells.  
       
47
MAG OD
450
SGPG OD
450
EBNA1 OD
450
0 1 2 3 40.0
0.5
1.0
1.5
2.0
ug/w
ell
2°
 0.05
0.1 0.5
 1
5 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
PC
0.0
0.5
1.0
1.5
2.0
 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
 0.0001 0.0005 0.01 0.05
0.1 0.5
 1
5
P
9
P
11
P
5
P
10
P
27
8-18C
5
P
27
P
14
C
ontrol
IgM
 m
em
ory expansions
N
on expanded
48
EVQ L L E SGGG L VQ PGG S L R L SCAA SG F I F K T YGMTWV RQA PGKG L EWV S F VN SGGV T
EVQ L L E SGGG L VQ PGG S L R L SCAA SG F T F S SY AM SWV RQA PGKG L EWV SA I SG SGG S
EVQ L V G SGGG L VQ PGN S L R L SCAA SG F T FD D Y AMHWV RQV PGKG L EWV AG I TWN SGA
EVQ L V E SGGG L VQ PGR S L R L SCAA SG F T FD D Y AMHWV RQA PGKG L EWV SG I SWN SG S
QVQ L VQ SGD E R S LD L RKV SY EA SGY T F T T H T I HWV RQA PGQR P EWMGW I NGGNGD
QVQ L VQ SGA E V KK PGA SV KV SCKA SGY T F T SY AMHWV RQA PGQR L EWMGW I NAGNGN
QVQ LQQWGAG L V K P S ET L S L T CAV SGG S F S G F Y CNWF RQ P PGKG L EW I GQ MN P SGG-
QVQ LQQWGAG L L K P S ET L S L T CAV YGG S F S GY YWSW I RQ P PGKG L EW I GE I NH SG S-
EVQ L V E SGGG L VQ PGG S L R L SCAG SAV S FN T YWMTWV RQA PGKG L EWV A S I KKD E S E
EVQ L V E SGGG L VQ PGG S L R L SCAA SG F T F S SYWM SWV RQA PGKG L EWV AN I KQDG S E
T F Y AD SV KGR F T I SRDN SKN T V Y LQMN S L R V ED T AV Y Y CA RGGAAV GV GT NWLD PWG
T Y Y AD SV KGR F T I SRDN SKN T L Y LQMN S L R A ED T AV Y Y CA K - - - - - - - - - - - - - - - -
I GY AN SV KGR F T I SRDNAKK S L Y LQMN S L R V ED T A F Y Y CT SGRGET - - - - - RGAHWG
I GY AD SV KGR F T I SRDNAKN S L Y LQMN S L R A ED T A L Y Y CA KD - - - - - - - - - - - - - - -
T KY SQK FQGR I T I T RD T SAT T V FMD L S S L I S ED T AV Y Y CV RGGR- - - - - - I S PH LWG
T KY SQK FQGR V T I T RD T SA S T AYM E L S S L R S ED T AV Y Y CA R- - - - - - - - - - - - - - - -
T SYN PT L K SR V T T S LD T SRK Q F S L K LD SV T AAD T A I Y Y C S R SR SGEN - - - - - - - I WG
T N YN P S L K SR V T I SVD T SKN Q F S L K L S SV T AAD T AV Y Y CA R- - - - - - - - - - - - - - - -
KY Y VD SV RGR F T I SRDNAK S S L F LQ LN S L S GDD T AV Y Y CA R L RMGCD - - - GWLD YWG
KY Y VD SV KGR F T I SRDNAKN S L Y LQMN S L R A ED T AV Y Y CA R- - - - - - - - - - - - - - - -
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The germline VH elements and the expanded mutated heavy chain amino acid sequences were 
aligned with each other. The corresponding germline amino acid sequence of the expanded 
IgM memory B cell is depicted below each sequence. The alignment was performed with the 
T-coffee alignment algorithm. The letter color indicates the homology of the amino acids red 
reflects 0% black 50% and blue 100% identity. The grey box shows different residues. For 
the consensus sequence a conservation of 80% was defined. On the left side the germline 
identity for each clone is shown. The identity was calculated with the IMGT web tool.
Figure 23: Alignment of the 5 expressed IgM memory expansions
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Responder vs non-responder
Next, we determined whether patients showing a clinical improvement following Rituximab treat-
ment, hereafter referred to as clinical responders (n = 4), can be distinguished from patients with stable 
or worsened disease, i.e. clinical non-responders (n = 9), through IgH chain gene repertoire changes, 
CDR3 characteristics, and the kinetics of clonal expansions during Rituximab treatment. The clinical 
response	was	quantified	using	a	standardized	clinical	disability	scale	and	details	are	reported	in	the	
publication of the clinical trial 206. Data obtained in clinical responders and non-responders were com-
pared to placebo-treated patients (n = 6) and age-matched healthy control (n=3). 
VH and DH	gene	family	usage	in	circulating	naïve,	IgM	memory	and	IgG	memory	B	cells	before	treat-
ment initiation did not differ between these clinical subgroups and peripheral B cell reconstitution did not 
significantly	alter	the	VH and DH gene repertoire one year after treatment  (Figure 16 , 17 and 18). Before 
therapy, JH5 usage was more frequently found in clinical responders compared to non-responders, 
but	 these	 differences	 lost	 statistical	 significance	 12	 months	 after	 Rituximab	 therapy	 (Figure	 18).	 
These data indicate that the clinical response to Rituximab therapy is not associat-
ed	 with	 significant	 changes	 in	 the	 VH, DH and JH	 gene	 family	 usage	 of	 naïve	 and	 mem-
ory	 B	 cells.	 The	 modest	 increase	 in	 CDR3	 lengths	 in	 the	 naïve	 B	 cell	 compartment	 fol-
lowing peripheral B cell reconstitution, could be attributed to clinical non-responders 212. 
A	much	more	 important	finding	 in	 the	CDR3	analysis	of	 responder	and	non-responder	was	 the	 in-
sufficient	 selection	 of	 the	 CDR3	 usage	 in	 respect	 to	 length	 and	 isoelectric	 point	 compared	 to	 
age-matched	healthy	controls.	Healthy	controls	show	a	significant	selection	of	shorter	CDR3	in	the	
IgM	memory	and	IgG	memory	compartment	compared	to	naïve	B	cells	 86. A similar trend was ob-
served for the isoelectric point, where the CDR3 is selected towards higher pH starting from the mature 
naïve	to	the	IgG	memory	B	cell	compartment	in	healthy	controls.	These	changes	in	the	CDR3	might	
reflect	 different	 checkpoints	 in	 the	 development	 from	 naïve	 to	 IgM	 and	 IgG	memory	B	 cells	 12,86. 
The length of the CDR3 in the case of responder patients shows no selection before the therapy and 
after the Rituximab treatment there is a clear stepwise shortening of the CDR3 length similar to the 
healthy control (Figure 24). 
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Patients showing a clinical improvement following therapy were classified as Rituximab re-
sponders, patients with stable or worsened disease severity were classified as Rituximab 
non-responders. The same number of individual IgH chain gene sequences derived from 
Rituximab-treated patients as displayed in Figure 16 were analyzed and the results are dis-
played as data derived from individual sequences. Data points represent individual sequenc-
es. Horizontal bars and error bars indicate mean ± SEM. The unpaired student t-test was 
used to evaluate IgH chain characteristics
Figure 24: Comparison of the CDR3 of responder, non-responder healthy control in the  
       context of length and PI
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Non-responders display a reduced length after the therapy only for the IgG memory B cells. In the 
placebo	group	the	CDR3	length	drop	significantly	(P=0.001)	from	an	average	of	15.7	AA	in	the	naïve	
B cells down to 14.12AA in the IgM memory B cell compartment, which is more pronounced in all 
the	pooled	anti-MAG	neuropathy	patients	before	therapy	(P<0.0001).	But	there	was	no	change	com-
paring	naïve	B	cells	with	IgG	memory	B	cells.	For	the	isoelectric	point	we	see	a	significant	selection	
in the responder before the therapy but only from the IgM memory to the IgG memory compartment, 
which is similar to the healthy control. The difference to healthy controls is that the healthy controls 
have a stepwise increase of the isoelectric point during the maturation. Since only 3 healthy controls 
were	used	the	increase	from	the	naïve	to	the	IgM	memory	B	cell	compartment	might	not	be	significant.	
Responders	show	a	lake	of	selection	from	the	naïve	to	the	IgM	memory	compartment	before	therapy	
(Figure 24). After Rituximab the CDR3s have a shift to higher pH in the IgM- and IgG memory com-
partment.	The	significance	between	the	IgM-	and	IgG	memory	B	cell	CDR3	pH	is	lost	(Figure	24).	The	
Placebo group has no change in the pH of the isoelectric point between all the compartments similar as 
the non-responders. Since the analysis in Figure 23 was performed with pooled sequence data we ad-
ditionally analyzed the groups with mean values of the single patients with the paired Wilcoxon signed 
rank	test.	The	result	that	we	received	reflects	a	similar	situation	as	for	the	pooled	sequence	data	for	
the	non-responders	(CDR3	length	naïve	after	vs	IgG	memory	after	P=0.0078).	The	significance	in	the	
responder group was lost due to the small sample size. 
We observed that clinical non-responders started with a higher load of IgM memory B cell 
expansions	 compared	 to	 patients	 who	 had	 a	 clinical	 benefit	 from	 Rituximab	 (p=0.0043)	 
(Figure 25). Moreover, the reduction of IgM memory B cell expansions following B cell depletion 
as determined by IgH gene sequence analysis was less strong in non-responders (expansions were 
reduced by a factor of 1.3) compared to clinical responders (expansions were reduced by a factor 
of 2.7). Consequently, the amount of IgM memory B cell expansions remained increased in treat-
ment	non-responders	compared	to	responders	following	peripheral	B	cell	reconstitution	(p	=	0.0041).	 
Notably, clinical responders that were included in our study showed a higher than 2-fold decrease in 
MAG-specific	IgM	antibody	titers206	indicating	that	inhibition	of	MAG-specific	B	cell	expansions	is	
associated	with	inhibition	of	pathogenic	MAG-specific	antibody	secretion.	However,	we	did	not	de-
tect	a	significant	correlation	between	MAG-titers	and	the	size	of	clonal	IgM	memory	expansions	in	 
individual patients.
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Since the Ig gene repertoire analysis is based on pooled individual sequences, we 
additionally analyzed the proportions of clonal expansions per individual patient and compared 
the mean proportions between both Rituximab-treated subgroups, i.e. 4 responder and 9 non-re-
sponder. In line with the analysis based on sequences, clinical non-responders tended to start with 
a higher load of IgM memory B cell expansions compared to patients who had a clinical ben-
efit	 from	Rituximab	 and	 the	 amount	 of	 IgM	memory	B	 cell	 expansions	 tended	 be	 higher	 in	 treat-
ment non-responders compared to responders following peripheral B cell reconstitution (Figure 26). 
The	statistical	significance	was,	however,	lost,	possibly	due	to	the	small	sample	size.	Both	the	analysis	
of pooled sequences and of sequences per individual patient did not detect any changes in the Ig gene 
family usage during Rituximab therapy. Continuous as well as categorical outcomes per individual 
patient are shown in Table 5.
We	identified	several	identical,	expanded	IgM	memory	B	cell	clones,	which	persisted	for	12	months	in	
individual placebo-treated patients as well as in clinical non-responders P5 and P23 (Figure 26). 
Persisting clonal expansions were not observed in clinical responders suggesting that these persisting 
expansions may have contributed to the progression of the disease (Figure 26), although we cannot 
exclude the possibility that persisting, low-abundant clonal expansions would have been detected if a 
larger number of samples had been analyzed. Frequencies of expanded sequences per individual pa-
tients are listed in the Table 4.
A
Responder (R) Non Responder (NR)
Before Rituximab treatment After Rituximab treatment
Responder (R) Non Responder (NR)
P=0.0041P=0.0043
expansionsnon expanded sequences
202 451 102 223
IgM memory expansions before and after therapy in pooled samples from Rituximab respond-
er and Rituximab non-responder. Results are based on the analysis of individual sequences in 
both clinical subgroups. The numbers in circles indicate the number of individual sequences 
per patient cohort that were analyzed. The two-tailed Fisher`s exact test was used to compare 
proportions of clonal expansions
Figure 25: The IgM memory B cell expansions in responder and non-responder  
       before and after therapy
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before after before afterbefore after
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non expanded sequences
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P17P6
P18
P26
P22
P8
P21
31 45
57 40
7432 31
30 25
68 38
4 4
cloned expanded sequences
ND
ND
clonal persistence
ND not determined
IgM memory B cell expansions in individual patients classified as Rituximab responder or non-
responder compared to placebo-treated patients. Non-expanded sequences are highlighted 
in grey, clonally expanded CDR3 sequences are highlighted in different colors. Sequences 
that were detected before and after therapy in individual patients are highlighted in black. Ex-
panded sequences that were resurrected as IgG monoclonal antibodies, whose specificities 
are shown in Figure 3B, are marked with circles. ND denotes not determined: due to the low 
frequency of memory B cells in these 2 post-Rituximab samples, we were not able to amplify 
PCR products.  
Figure 26: The clonal expansions in the IgM memory compartment of individual patients
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Patient Subgroup  
Before versus. 
After therapy
Patient Memory compartment Before Frequency of exp. seq. 
(%)
Placebo P8 IgM after 7/45 (15.6%)
Placebo P8 IgM after 2/45 (4.4%)
Placebo P8 IgM after 2/45 (4.4%)
Placebo P8 IgM after 2/45 (4.4%)
Placebo P8 IgM after 2/45 (4.4%)
Placebo P8 IgM after 2/45 (4.4%)
Placebo P8 IgM before 12/31 (38.7%)
Placebo P8 IgM before 3/31 (9.7%)
Placebo P8 IgG before 2/37 (5.4%)
Placebo P8 IgG before 3/37 (8.1%)
Placebo P8 IgG before 2/37 (5.4%)
Placebo P8 IgG after 3/31 (9.7%)
Placebo P9 IgM before 31/43 (72.1%)
Placebo P9 IgM before 2/43 (4.7%)
Placebo P9 IgM after 45/67 (67.2%)
Placebo P9 IgM after 3/67 (4.5%)
Placebo P9 IgG after 20/60 (33.3%)
Placebo P9 IgG after 2/60 (3.3%)
Placebo P9 IgG after 2/60 (3.3%)
Placebo P9 IgG after 2/60 (3.3%)
Placebo P11 IgM before 12/13 (92.3%)
Placebo P11 IgM after 8/24 (33.3%)
Placebo P11 IgM after 4/24 (16.7%)
Placebo P11 IgM after 2/24 (8.3%)
Placebo P11 IgM after 2/24 (8.3%)
Placebo P13 IgM after 2/16 (12.5%)
Placebo P16 IgM after 3/29 (10.3%)
Placebo P16 IgM after 2/29 (6.9%)
Placebo P21 IgM before 4/57 (7.0%)
Placebo P21 IgM before 2/57 (3.5%)
Responder P3 IgM after 2/37 (5.4%)
Responder P3 IgM after 2/37 (5.4%)
Responder P3 IgG after 3/16 (18.8%)
Responder P14 IgM before 6/49 (12.2%)
Responder P14 IgM before 2/49 (4.1%)
Responder P14 IgM before 2/49 (4.1%)
Responder P14 IgG after 2/9 (22.2%)
Responder P27 IgM before 7/44 (15.9%)
Responder P27 IgM before 4/44 (9.1%)
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Patient Subgroup  
Before versus. 
After therapy
Patient Memory compartment Before Frequency of exp. seq. 
(%)
Non-responder P5 IgG after 2/44 (4.5%)
Non-responder P5 IgG before 2/38 (5.3%)
Non-responder P5 IgM after 5/20 (25%)
Non-responder P5 IgM after 4/20 (20%)
Non-responder P5 IgM after 4/20 (20%)
Non-responder P5 IgM before 19/78 (24.4%)
Non-responder P5 IgM before 2/78 (2.6%)
Non-responder P6 IgM before 2/32 (6.3%)
Non-responder P6 IgM before 2/32 (6.3%)
Non-responder P6 IgM before 2/32 (6.3%)
Non-responder P6 IgM after 3/31 (9.7%)
Non-responder P10 IgG before 2/35 (5.7%)
Non-responder P10 IgM after 2/53 (3.8%)
Non-responder P10 IgM before 3/58 (5.2%)
Non-responder P10 IgM before 2/58 (3.4%)
Non-responder P10 IgM before 24/58 (41.4%)
Non-responder P12 IgM before 3/43 (7.0%)
Non-responder P12 IgM before 2/43 (4.7%)
Non-responder P17 IgM before 2/74 (2.7%)
Non-responder P17 IgM before 2/74 (2.7%)
Non-responder P17 IgM before 10/74 (13.5%)
Non-responder P17 IgM before 2/74 (2.7%)
Non-responder P17 IgG after 2/33 (6.1%)
Non-responder P18 IgG after 2/23 (8.7%)
Non-responder P22 IgG after 2/3 (66.7%)
Non-responder P22 IgM before 2/30 (6.7%)
Non-responder P22 IgM after 2/25 (8.0%)
Non-responder P23 IgM after 6/43 (14.0%)
Non-responder P23 IgM after 2/43 (4.7%)
Non-responder P23 IgM before 2/64 (3.1%)
Non-responder P23 IgM before 2/64 (3.1%)
Non-responder P23 IgM before 2/64 (3.1%)
Non-responder P23 IgM before 2/64 (3.1%)
Non-responder P23 IgM before 1
Non-responder P26 IgM after 4/38 (10.5%)
Non-responder P26 IgM after 2/38 (5.3%)
Non-responder P26 IgM after 2/38 (5.3%)
Frequency of expanded sequences in the memory compartment of all patients before and af-
ter therapy are depicted as frequency of expanded sequences divided by the total sequence 
count for each patient.
Table 4: Frequency of expanded sequences in the memory compartment
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To further address whether IgM memory B cells in Rituximab-treated patients developed newly or 
persisted over time, we compared the frequency of SHM in IgM memory B cells before and after 
therapy. Comparing the SHM level of all the anti-MAG neuropathy patients before treatment with age-
matched healthy controls did not show any difference. The only exception is P27, which was excluded 
in this analysis due to its exceptional high level of SHM (Figure 27). The degree of SHM was stable in 
placebo-treated	patients	(Figure	28A).	Likewise	and	despite	efficient	depletion	of	circulating	B	cells,	
the overall SHM frequency in circulating IgM memory B cells remained unchanged in clinical non-
responders (Figure 28A). 
Mean SHM frequencies of CD19+CD27+IgM+ memory B cells in framework- and CDR-regions 
(FWR1, CDR1, FWR2, CDR2 and FWR3). P27 was excluded from the data, due to its elevated SHM 
levels. Expanded sequences were taken into account only once in order to analyze SHM 
frequencies in IgM memory B cells independent from clonal expansions. Results are based 
on the analysis of individual sequences in clinical subgroups. The unpaired student t-test was 
used to compare SHM frequencies.
Figure 27: The SHM level in the IgM memory compartment of anti-MAG neuropathy patients
       is normal compare to age-matched healthy donors
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In	 contrast,	 clinically	 effective	Rituximab	 treatment	was	 associated	with	 a	 significant	 reduction	 in	
the	SHM	frequency	in	variable	region	of	IgM	memory	BCR	(p	=	0.0001)	(Figure	28A).	Notably,	the	
frequency of somatic mutations in clinical responders, was higher before but lower 12 months after 
Rituximab therapy compared to non-responders (Figure 28B). 
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Total mutations of the VH before Rituximab treatment
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Total mutations of the VH after Rituximab treatment
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A) Mean SHM frequencies of CD19+CD27+IgM+ memory B cells in framework- and 
CDR-regions (FWR1, CDR1, FWR2, CDR2 and FWR3) in placebo-treated patients 
(left diagram), Rituximab-treated responders (middle diagram), and Rituximab-treated 
non-responders (right diagram) before and after Rituximab therapy.  B) Mean SHM fre-
quencies before (left diagram) and after Rituximab therapy (right diagram) in patients 
who showed a clinical benefit from Rituximab therapy as compared to patients with sta-
ble or worsened disease 12 months after treatment, i.e. clinical non-responder. Expand-
ed sequences were taken into account only once in order to analyze SHM frequencies in 
IgM memory B cells independent from clonal expansions. Results are based on the analy-
sis of individual sequences in clinical subgroups. The unpaired student t-test was used to 
compare SHM frequencies.
Figure 28: Lack of changes in somatic hypermutation (SHM) frequencies in IgM memory B
       cells are associated with a poor clinical response to Rituximab
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The reduction after therapy was strongest in patient P27 who showed the strongest clinical improve-
ment in response to Rituximab as compared to all clinical responders. But all of the clinical responders 
showed the same trend of  SHM reduction after therapy (Figure 29). The overall SHM level in the IgM 
memory compartment is normal compared to healthy control for responders and non-responders. The 
only	exception	is	again	P27,	which	has	a	significant	elevated	level	of	SHM	for	the	total	variable	region	
of	the	IgM	memory	compartment.	The	reduction	of	mutations	reflects	the	renewal	of	the	IgM	memory	
compartment in responder patients.
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Mean SHM frequencies of CD19+CD27+IgM+ memory B cells in framework- and CDR-regions 
(FWR1, CDR1, FWR2, CDR2 and FWR3). The 3 responding patients show a reduced SHM 
frequency after Rituximab therapy.
Figure 29: The individual SHM reduction in the IgM memory compartment for three  
       individual responder patients before and after Rituximab treatment
To	further	validate	our	interesting	finding	of	SHM	in	the	IgM	memory	compartment	we	sorted	and	
sequenced	the	naïve	B	cells	as	negative	control	and	the	IgG	memory	B	cell	compartment	as	clearly	GC	
deriv d	SHM	positive	control	(Figure	30A	and	B).	
As	expected,	the	non-expanded	(CD19+	CD27-	IgM+)	naïve	B	cells	show	a	very	low	percentage	of	
base	pair	exchange	before	and	after	the	therapy,	which	reflects	the	unchanged	germline	sequence	of	
the	naïve	B	cells	after	VDJ	recombination.	This	finding	is	true	for	placebo	treated,	Rituximab	treated	
patients	(Figure	30B)	and	age-matched	healthy	controls.	In	contrast	to	the	IgM	memory	compartment	
we	found	no	significant	reduction	in	SHM	frequency	in	the	IgG	memory	B	cell	compartment	compar-
ing	responder	and	non-responder	(Figure	30A).	
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A)
B)
Mean SHM frequencies of CD19+CD27+IgG+ memory B cells and CD19+CD27-IgM+ naïve B 
cells in framework- and CDR-regions (FWR1, CDR1, FWR2, CDR2 and FWR3)
A) illustrates the SHM level before and after Rituximab therapy for the three different patients 
groups placebo responder and non-responder. B) shows a similar analysis for the naïve B 
cell compartment.
Figure 30: SHM frequency in the IgG memory - and naïve B cell compartments
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Figure 31: The SHM level in the IgG memory compartment of anti- MAG neuropathy patients  
        is normal compares to age-matched healthy donors
A) Mean SHM frequencies of CD19+CD27+IgG+ memory B cells in framework- and CDR-
regions (FWR1, CDR1, FWR2, CDR2 and FWR3). Healthy donors and anti-MAG neu-
ropathy patients have a similar level of SHM in the IgG memory compartment. MAG 
stands for anti-MAG neuropathy and HD for healthy donors B) The level of SHM in the 
IgG memory compartment is elevated compared to the IgM memory compartment. 
For A) and B) expanded sequences were taken into account only once in order to ana-
lyze SHM frequencies in IgM and IgG memory B cells independent from clonal expan-
sions. Results are based on the analysis of individual sequences in clinical subgroups. 
The unpaired student t-test was used to compare SHM frequencies.
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The overall SHM level is the same before and after the Rituximab therapy and is compara-
ble between placebo, Rituximab treated responder and non-responder patients and healthy control 
Figure	 31A.	 The	 SHM	 in	 the	 IgM	 memory	 compartment	 is	 significantly	 lower	 than	 in	 the	 
IgG	memory	compartment,	which	reflects	the	high	proliferation	and	the	high	AID	expression	in	the	GC	
IgG memory B cells (Figure 31B).
Our study demonstrates that the long-term immunomodulatory effects of Rituximab in anti-MAG 
neuropathy are mediated through the sustained reduction of expanded autoreactive IgM memory B 
cells. In patients with peripheral nervous system autoimmunity associated with IgM MGUS, which 
is believed to arise from somatically hypermutated but non-class-switched B cells that acquire IgM 
secretory capacity 213,214, we show that IgM memory B cells contain an important reservoir of auto-
reactive species and that the sustained elimination of these cells is associated with clinical disease 
remission. Conversely, high load and clonal persistence of expanded autoreactive IgM memory B cell 
clones	despite	efficient	depletion	of	circulating	B	cells	were	associated	with	a	poor	clinical	response	
to Rituximab. 
Previous	studies	demonstrated	expansion	and	persistence	of	foreign	antigen-specific	memory	B	cells	
following infection and vaccination 215-217 and of candidate pathogenic T cell clones in human autoim-
mune diseases such as multiple sclerosis and type 1 diabetes	218-220. The known identity of the target 
antigen allowed us to address the dynamic behavior of expanded autoreactive B cells in patients with 
anti-MAG neuropathy. The presence of oligoclonal expansions within the IgM memory B cell com-
partment before treatment initiation, their ability to recognize MAG protein and their persistence in the 
group of patients with stable or worsened disease suggest that these persisting expansions may have 
contributed	to	disease	progression	and	argue	for	an	important	role	of	MAG-specific	IgM	memory	B	
cells	in	the	pathogenesis	of	this	inflammatory	neuropathy.
Clinical	 responders	 showed	 qualitative	 immunological	 changes	 that	 indicate	 reconfigura-
tion of B cell memory through sustained reduction of autoreactive expansions and changes in 
somatic mutation frequencies in the IgM memory compartment. While these changes might be 
driven by different B cell linages, we were not able to distinguish them with the staining we used 
due to color limitations on the FACS Aria I machine. The different lineages are namely marginal 
zone (MZ) B cells, B1 B cells and IgM+	 first	 round	germinal	 center	B	 cells	 that	 contribute	 to	 the	 
CD27+IgM+ B cell pool. The lack of resolution leads to speculation about the origin of the 
MAG-recognizing	IgM	antibodies.	The	first	population	I	would	 like	 to	discuss	are	 the	MZ	B	cells,	
which are located in the marginal zone of the spleen. The marginal zone (MZ) in the spleen is an 
anatomical structure between the red and the white pulp 221. In humans the MZ B cells (CD27+IgM+IgD+) 
form a double-layer with a T cell layer in-between. In rodents the MZ forms a monolayer 222. 
Discussion
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B cells with a MZ B cell surface marker phenotype are found as well in the inner wall of the 
subcapsular sinus in lymph nodes, in the crypt epithelium of tonsils and under the dome epithelium of 
Peyer’s	patches	223-227. Evidence for distinct MZ B cell maturation sites apart from the spleen are found 
in patients with congenital asplenia as well as splenectomized patients, which still have MZ B cells but 
in a lower frequency compared to healthy humans 228.	The	frequency	of	MZ	B	cells	is	15-20%	of	all	B	
cells and represents the largest IgM+ fraction in the memory compartment 223 (Figure 32A).
MZ	B	cell	precursors	develop	during	the	first	years	after	birth	and	start	to	populate	the	spleen.	These	
precursors separate from the follicular B cell maturation path after passing the T2 223 or the mature 
naïve	stage	13 and have the capacity to self-renewal 229. It is not clear if the cells repopulate the spleen 
in one wave during ontogeny or if the population is slowly renewed 223. Some evidence was found in 
bone marrow-transplanted humans, which have a similar repopulation time as newborns 230 and in au-
toimmune	patients	with	RA	treated	with	an	anti	human	CD20	antibody.	In	the	case	of	B	cell	depleted	
RA	patients	the	MZ	B	cell	recovery	rate	is	less	then	1/3	of	the	initial	population	after	2	years	231. These 
findings	might	support	the	concept	of	a	constant	renewal	of	the	MZ	B	cells	from	blood	borne	precur-
sors;	on	the	other	hand	the	influx	of	new	cells	is	not	enough	to	refill	the	spleen,	which	indicates	that	a	
certain self-sustaining capacity may exist. 
In	the	MZ	region	mature	naïve	or	T2	B	cells	develop	in	a	T	cell-independent	manner	(TI)	TI-1	and	
TI-2 to MZ B cells 232.	TI-1	is	dependent	on	BCR	activation	and	stimulation	with	BAFF	and	APRIL	98 
and TI-2 is based on the repetitive crosslinking of the BCR due to a repeating epitope, which clusters 
the BCR and starts to signal 99,100. The MZ B cells are natural effector B cells because they are reacting 
to blood borne pathogens like Streptococcus pneumoniae in an innate immune response-like manner 
85.	MZ	B	cells	are	able	to	produce	large	amounts	of	IgM	antibodies	3-4	days	after	TLR	stimulation	
233.	In	contrast	to	mature	naïve	B	cells	MZ	B	cells	express	a	large	set	of	TLR	(2,6,7,8,9,10)	similar	to	 
class -switched B cells 234-236, which is important to reduce the response time towards blood borne 
pathogens. 
Concerning the level of SHM in the variable region of the BCR, the MZ B cells do have similarities to 
a GC derived memory B cells in humans (Figure 32B). The immunoglobulin variable regions of these 
cells	are	mutated	and	show	features	of	affinity	maturations	in	humans	but	not	in	rodents	224,237,238. The 
frequency	of	mutations	is	approx.	50%	less	than	for	a	GC-derived	memory	B	cell	223,239,240 (Figure 32B). 
How the mutations are introduced in a human MZ B cell is not clear.
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Figure 32: Marginal zone B cells vs. GC B cells 
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A) Shows the frequency of marginal zone B cells compared to class switch memory B cells. 
B) Illustrates percent base pare exchange in the JH4 gene segment in blood of marginal zone 
B cells and class switched memory B cells. C) Demonstrates the different length distribu-
tion of the CDR3 of VH3-15 gene segment containing B cells in different B cell linages of the 
blood in an 11-month old child. D) Similar as in C) but in the spleen of an 8-month old child. 
The Figure is adapted from223,242
 The general process for SHM induction is AID related but in immunohistochemical assays the protein 
could not be detected 241 and in qRT-PCR only low levels of AID expression were found in children 
below the age of 2 years 242.	Evidence	for	an	AID	involvement	was	found	in	AID-deficient	patients,	
which lack mutations in the variable region of immunoglobulins 228.
The overall antibody repertoire of MZ B cells is less restricted than for normal memory B cells. This 
means that the BCR selection is not as stringent as in the GC reaction, where only a couple of BCR 
are favored. The restriction of the BCR can be measured by the length distribution of the CDR3 (spec-
tratyping).	Analysis	of	 the	MZ	B	cells’	CDR3	 length	by	spectratyping	showed	 less	 restriction	 than	
memory B cells. MZ B cells do have a quasi-gaussian distribution, compared to memory B cells with 
well-defined	spikes	of	the	CDR3	length	that	suggest	a	strong	selection	during	the	GC	reaction.	The	
overall	length	is	only	slightly	shorter	than	naïve	B	cells,	which	indicates	less	selection	in	the	MZ	of	the	
spleen 223,242 (Figure 32 C and D). 
One of the remaining questions concerning the MZ B cells is if these cells are in a transitional state 
and undergo CSR later on or if MZ B cells are the endpoint of their development. Evidence for 
subsequent CSR was found in vitro	by	treating	the	MZ	B	cells	with	CD40L	and	measuring	IgG	levels.	
In comparison to CD27+IgM+IgD- GC memory B cells MZ B cells have a higher capacity to undergo 
immunoglobulin class-switching 243. Puga et al. showed in a recent study that neutrophils in the spleen 
do	express	CD40L	and	are	able	to	induce	CSR	in vitro in a co-culture with MZ B cells 244.
Kruetzmann et al. showed effector B cell function in the IgM+IgD+CD27+ B cell compartment due to 
TLR	stimulation	85.	It	might	be	possible	that	the	pathogenic	B	cells	are	derived	from	the	MZ	B	cells,	
which is the largest population in the CD27+IgM+ B cell compartment 223 (Figure 15). However there is 
the	new	finding	from	Griffin	et	al.,	where	they	demonstrated	the	presence	of	the	B1	B	cells	in	humans	
in	2011.	They	distinguished	two	subsets	of	B1	B	cells	with	similar	functions	as	B1a	and	B1b	cells	in	
the mice 245,246	and	a	similar	phenotype	as	Kruetzmann	defined	for	the	MZ	cells	85.
In	mice	the	B1	B	cells	were	described	first	by	Lanier	et	al.	in	1981.	He	found	a	B	cell	tumor	with	a	
characteristic expression of CD5 in mice 247. These cells were then further characterized and subdi-
vided into two populations being B1a (sIgM CD11b+ CD5+) and B1b B cells (sIgM CD11b+ CD5-) 248. 
Compared to the B2 B cells (all other B cells) the localization of the B1 B cells differs in mice. Few 
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B1 cells are found in the spleen but the majority of the cells are located in the peritoneal cavity 249-251. 
Murine B1 B cells are thought to be the natural effector B cells as they have the capacity to secret IgM 
in a TI manner, activate T cells and show high levels of phosphorylation of phospholipase C gamma 2 
(PLC-γ2)	and	Syk	245. 
Various	experiments	were	performed	to	find	out	the	progenitors	of	the	B1	B	cells.	Therefore	the	mice	
were irradiated and reconstituted with bone marrow or cells isolated from fetal liver and only mice re-
constituted with fetal liver-derived cells were able do reconstitute the B1 cell compartment 252,253. The 
bone marrow was only able to reestablish the B2 B cells. Wardemann could show that only mice with 
a functional spleen reconstituted with a fetal liver cells were able to generated B1a B cells and that 
these cells were able to respond to a TI vaccine (Pneumovax®23) 254. Montencine-Rodriguez was able 
to	isolate	a	B1	progenitor	(Lin-CD93+ CD45R-or lo CD19+) from fetal liver with the highest numbers 
peaking at day 17 of gestation in mice 255. These cells can differentiate in vitro and in vivo into B1a and 
B1b B cells and do not generate other hematopoietic lineages.
Griffin	 and	Rothstein	 discovered	 a	B1	B	 cell	 homologue	 in	 humans	 very	 recently	 245. The human 
B1 B cell lineage (CD27+IgM+IgD+CD43+CD70-CD69lo) has similar functional properties as the B1 B 
cells in the mice and their frequency is age dependent. The frequency of the B1 B cells is highest in 
umbilical cord blood of newborns and declines with aging 245. Furthermore, they were able to show 
that human B1 B cells have two subpopulations with or without CD11b expression. Interestingly, 
the CD11b+	cells	do	express	CD86	and	are	able	to	activate	T	cells	very	efficiently	in vitro 246. These 
CD27+ CD43+CD11b+	cells	occur	at	frequencies	of	about	10%	of	all	the	B1	B	cells	in	adult	peripheral	
blood	and	umbilical	cord	blood.	In	SLE	the	level	of	CD27+CD43+CD11b+ cells is elevated in the blood 
and	the	CD86	expression	is	significantly	higher.	Blocking	of	CD86	via an anti CD86 antibody was able 
to reduce the T cell activation in vitro 246. 
The VH	region	of	the	B1	B	cells	does	not	differ	from	the	naïve	B2	B	cells	in	terms	of	mutations,	N1/
N2 additions and CDR3 length but the use of different gene segments during the VDJ recombina-
tion	distinguishes	B1	from	B2	B	cells.	Especially	IGHV	3-30	and	IGHV1-2	are	elevated	in	the	B1	
cells 245. Due to the ability of these cells to secret IgM antibodies anti-MAG neuropathy might be 
mediated via B1 B cells 245,246. But the overrepresentation of the VH	3-30	and	VH1-2 element is not 
present in the expanded sequences of the anti-MAG neuropathy patients. This and the declining 
frequency of B1 B cells in aging people speaks against the involvement of B1 B cells in anti-MAG neu-
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ropathy 245.	The	last	possible	B	cell	population	is	the	first	round	germinal	center	B	cells	population,	which	
is characterized as IgM+IgD-CD27+ B cells. This population has the lowest frequency in the IgM memory 
compartment 223	(Figure	32A).	This	low	frequency	makes	it	difficult	to	address	the	pathological	role	of	
the GC IgM memory B cells.
The uncertainty of the pathogenic antibodies origin makes it necessary to use a new staining panel, 
which includes IgD, CD43, and CD11b as additional markers. These markers would make it possible 
to dissect the IgM memory compartment in MZ B cells (CD27+IgM+ IgD+ CD19+ CD43? CD11b? 
CD70?), B1 B cells (CD27+ IgM+ IgD? CD19+ CD43+ CD11b+/-) and the GC derived IgM memory B 
cells (CD27+ IgM+ IgD- CD19+ CD43- CD11b-).	Lets	assume	that	the	pathological	B	cells	are	the	MZ	
B	cells.	This	would	implicate	that	the	MZ	B	cells	secrete	IgM	due	to	TLR	stimulation	85 or the MZ B 
cells are further maturing to plasma cells, which was proposed by Puga et al 244. Then the checkpoint 
in the spleen must be affected. Since the MZ B cells are anyway not that strongly selected the failing 
of that checkpoint could be much likely. However, B1 B cells are spleen-dependent as well the T1 and 
T2	B	cells	have	to	pass	checkpoint	in	the	spleen,	which	reflects	the	important	role	of	the	spleen	and	the	
many layers of selection in this organ 13,87,254. 
Evidence for an involvement of a failing checkpoint can be seen in the selection of the CDR3 regions 
in respect to isoelectric point and length 12,86 (Figure 24). The data suggest that the non-responders have 
a weaker checkpoint selection before and after Rituximab therapy and that the responders restore the 
checkpoint after therapy compared to healthy controls. Especially the selection of the isoelectric point 
is	restored	in	the	responders	after	therapy.	The	checkpoint	failure	between	the	naïve	and	IgM	memory	
compartment of non-responders could be one of the reasons for the progressive nature of the disease. 
But	since	both	groups	had	failed	this	checkpoint	before	the	therapy	particularly	between	the	naïve	and	
IgG memory compartment it might implicate that one of the checkpoints in the GC is failing. 
The	checkpoint	from	the	naïve	to	the	IgM	memory	compartment	can’t	be	dissected	very	clearly	due	
to the different B cell lineages in this population. But the absence of the GC checkpoint could give 
evidence for a failure in the maturation of GC-derived IgM memory B cells. Since the GC-derived IgM 
memory B cells are only a very small population in the blood compared to MZ B cells, the functional 
checkpoint of the MZ B cells could mask the pathogenic IgM memory cells. 
However, it could be although inverted and the MZ B cells are failing and due to the depletion and the 
slow recovery rate of MZ B cells the checkpoint of the GC IgM memory B cells turns visible in the 
assay.	Since	the	non-responders	do	not	have	a	depletion	as	complete	as	the	responder’s	the	checkpoint	
in the IgM memory compartment might be masked in the non responder. 
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The SHM frequency in the IgG memory compartment is unchanged after Rituximab mediated B 
cell depletion before and one year after the therapy for anti-MAG neuropathy patients and similar 
to	healthy	controls	(Figure	30A	and	31A).	This	finding	indicates,	that	the	turnover	of	IgG	memory	B	
cells is higher than in the IgM memory B cells compartment. The slow recovery of the IgM memory 
compartment also observed in Rituximab treated RA patients, where the repopulation of IgM memory 
B	cells	was	still	only	1/3	of	 the	initial	population	2	years	after	Rituximab	therapy	 231. On the other 
hand	we	could	find	a	 lot	of	clonal	expanded	IgG	memory	B	cells	after	Rituximab	mediated	B	cell	
depletion, which shows the opposite trend as in the IgM memory compartment, where the expansions 
are reduced in all the Rituximab treated patients. Compared to the IgM+ CD27+ memory B cells the 
IgG+ CD27+	memory	B	cells	are	well	defined	as	GC	reaction	derived	B	cell	population	and	the	clonal	
expansion could be due to a fast repopulation of the IgG memory compartment through the hyperpro-
liferation in the GC reaction. The Rituximab induced bottleneck situation and the hyperproliferation in 
the GC leads to an overrepresentation of newly formed clonally expanded GC-derived IgG memory B 
cells, which can be seen in Figure 21.
In	contrast,	based	on	the	lack	of	significant	changes	in	SHM	frequencies,	we	found	no	evidence	for	
a	significant	de	novo	generation	of	IgM	memory	B	cells	in	clinical	non-responders	suggesting	that	at	
least	a	fraction	of	disease-relevant	B	cells	were	not	accessible	for	or	susceptible	to	CD20	immuno-
therapy. In patients with rheumatoid arthritis, the depleting effect of Rituximab is reported to be more 
profound	in	the	peripheral	blood	than	in	inflamed	joints	or	bone	marrow257-259. Although the clinical 
response status was not addressed in the aforementioned studies, the results obtained here suggest that 
targeting of B cell-depleting antibodies to professional lymphoid tissues and sites of autoimmune in-
flammation	for	the	sustained	elimination	of	autoreactive	B	cells	might	increase	the	clinical	efficacy	of	
CD20	immunotherapy.	
Rituximab	was	evaluated	for	its	clinical	efficacy	in	anti-MAG	neuropathy	based	on	its	potential	to	re-
duce pathogenic IgM antibodies by depleting B cells. Initial uncontrolled phase II studies reported that 
some patients show clinical improvement following Rituximab therapy 260-262. Patients who initially 
responded well to Rituximab in one of the aforementioned clinical trials were prospectively observed 
without treatment for another 36 months. Despite the reappearance of circulating B cells, a sustained 
clinical	benefit	after	a	single	Rituximab	course	was	noted	that	lasted	up	to	24	months	in	80%	and	up	to	
36	months	in	60%	of	patients	263. Disease recurrence was best correlated with high baseline anti-MAG 
titers and increasing anti-MAG antibodies at follow-up and the authors suggested that patients with 
high anti-MAG titers may require additional courses with Rituximab 263. 
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In	a	small	series	of	eight	patients,	administration	of	a	double	dose	of	Rituximab	(750	mg/m²	every	
week	for	1	month)	17	to	27	months	after	standard	dose	treatment	(375	mg/m²)	improved	the	clinical	
outcome.	High-dose	treatment	was	also	efficient	in	inducing	a	first	clinical	response	associated	with	
reduced anti-MAG antibody titers in patients that were refractory to the standard treatment 262. 
What we can conclude from the study is that the low level of SHM and the absence of clonal persis-
tence indicated that newly developed B cells repopulated the IgM memory compartment in clinical 
responders. We found that a high load of oligoclonal B cell expansions before therapy and low ef-
ficiency	to	reduce	B	cell	expansions	with	Rituximab	is	associated	with	a	poor	clinical	response.	Our	
data,	suggest	that	patients	who	show	no	clinical	improvement	after	a	first	round	of	Rituximab	therapy	
could	benefit	from	additional	treatment	rounds	to	deplete	or	further	reduce	the	frequency	of	clonally-
related autoreactive B cells. 
The reason why the non-responder group has a weaker depletion has still to be addressed. One pos-
sibility	is	a	FcγR	mutation	which	reduces	the	efficacy	of	the	ADCC	mediated	depletion	of	Rituximab	
196-199.	To	further	address	this	point	the	patients	from	this	study	should	be	tested	for	FcγR	polymorphism	
and compared to the already obtained results. A possible solution to resolve the low B cell depletion 
efficacy	in	the	non	responder	is	the	third	generation	of	anti-CD20	antibodies	like	GA101,	which	have	a	
higher	binding	affinity	to	the	FcγR	200.		This	higher	binding	affinity	could	compensate	for	the	polymor-
phism in the non responder group.
Further	 the	 IgM	 memory	 compartment	 has	 to	 be	 dissected	 into	 B1,	 MZ	 and	 first	 round	 GC	 
IgM	memory	B	 cells	 lineages	 to	find	 the	 pathogenic	B	 cell	 population.	This	 could	 lead	 to	 a	more	
precise depletion strategy, which might reduce the side effects of the therapy and keeps the immune 
system more intact. To achieve this goal the pathogenic B cell linage has to be further characterized to 
find	specific	markers	that	are	not	present	on	the	other	B	cell	linages	and	on	any	other	cell	population	
in the body. 
The CDR3 results gives some evidence that one of the GC checkpoint might be involved in the 
disease development and this could indicate that the pathogenic B cell is a GC-derived IgM 
memory B cell. Since, the knowledge about how the selection mechanisms in B cells check-
points are working is still very limited, the knowledge of the pathogenic B cell population could 
give evidences about working mechanism of the checkpoints that are affected in the cause of 
the disease and could give a more insight view into the pathology of anti-MAG neuropathy. 
69
The deeper understanding of the checkpoints is crucial to understand not only anti-MAG neuropathy, 
it is as well important for all other autoimmune diseases with an antibody association.
Further the recombinant antibodies, which recognize MAG in a concentration dependent 
manner, should be used to generate an animal model to understand the pathological character of them. 
Due to the different VH element usage in the 5 expanded clones and the different CDRs it is likely that 
these clones recognize MAG via distinctive epitopes or that the avidity of the antibodies is changed 
(Figure 21). First the antibodies should be tested in a brain slice culture assay together with comple-
ment.	Since	mus	musculus	and	human	MAG	protein	has	a	high	amino	acid	homology	(94.5%)	this	
would give evidences, if the complement system is involved. Extra readout could be the IgM antibody 
deposits in the myelin sheet (Figure 4B), which are a pathological sign of anti-MAG neuropathy. Ad-
ditionally the antibodies could be injected into mice to establish an animal model for this rare disease. 
To achieve this goal the variable region of the antibodies has to be cloned into IgM backbone and ex-
pressed. The recombinant IgM antibodies are then intravenous injected and the animals are examined 
for neurological pathologies over several week.
In	conclusion,	our	data	indicate	that	the	therapeutic	efficacy	of	Rituximab	in	anti-MAG	neuropathy	
depends	on	efficient	depletion	of	non-circulating	B	cells	and	is	associated	with	qualitative	imunologi-
cal	changes	that	indicate	reconfiguration	of	B	cell	memory.	These	findings	provide	a	mechanistic	basis	
for the differential clinical response to Rituximab in anti-MAG neuropathy and support the therapeutic 
concept of ongoing and future clinical trials of B cell-depleting therapies in autoimmune diseases.
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We analyzed specimens form patients that were included in a double-blind, placebo-controlled study 
of Rituximab in patients with anti-MAG demyelinating polyneuropathy which was carried out at the 
National Institutes of Health in Bethesda, MD, USA (Table 5) 206. Patients were selected if they had 
clinical and electrophysiological evidence of a demyelinating neuropathy, a benign IgM monoclonal 
spike, and anti-MAG antibodies. Patients did not receive any immunosuppressive therapy for at least 
6 months before enrollment. At entry, all patients (except one) had impaired function as evidenced by 
affected	balance,	coordination,	frequent	falls,	or	muscle	weakness,	reflected	in	an	Inflammatory	Neu-
ropathy Course and Treatment (INCAT) disability score of at least 1. The study was conducted at the 
National Institutes of Health under a Cooperative Research and Development Agreement between Na-
tional Institute of Neurological Disorders and Stroke and Genetech. The trial was registered at www.
ClinicalTrials.gov	(ClinicalTrials.gov	number	NCT00050245),	and	was	conducted	under	a	protocol	
approved by the National Institute of Neurological Disorders and Stroke institutional review board. 
After	randomization,	four	weekly	intravenous	cycles	of	375mg/m2	of	Rituximab	or	placebo	consisting	
of	a	normal	saline	solution	were	administered.	Patients	were	premedicated	with	acetaminophen	650mg	
and diphenhydramine 25mg before infusions. The primary outcome was a change of at least 1 point in 
INCAT disability scale score in the lower extremities at month 8. This is a validated scale used before 
in	inflammatory	demyelinating	neuropathies	including	the	IgM	anti-MAG	neuropathy.	The	4	patients	
that	improved	by	at	least	1	INCAT	point	after	8	months	were	classified	as	Rituximab-responders;	the	
other patients with stable or worsened disease were classifed as non-responders. Individual demo-
graphical	and	clinical	profiles	of	all	patients	included	in	this	study	are	given	in	Table	1.	
Methods
Patients:
71
Flow cytometry and single cell analysis
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Gating strategy to identify naïve, IgM memory and IgG memory B cells before Rituximab 
therapy (A) and 12 months after treatment initiation (B). Panel A and B were generated with 
data from the same patient. Peripheral blood B cell frequencies from all live cells in the lym-
phocyte gate are shown in (C).
Figure 32: Sorting of single cells and frequency of the B cell in 
        anti-MAG neuropathy patients
Frozen	PBMCs	were	thawed	in	FACS	buffer	(2mM	EDTA,	5%	FCS,	20ug/ml	DNAse	Roche	in	PBS).	
After	thawing	the	PBMCs	were	strained	(0.22um	cell	strainer	Becton	Dickinson	(BD))	and	centrifuged	
for	15min	at	150xg	and	4°C.	The	cells	were	incubated	with	anti-CD27	PE	clone	M-T271,	anti-CD19	
PE-Cy7	clone	SJ25C1,	anti-IgM	APC	clone	G20-127,	anti-IgG	Biotin	G18-145,	streptavidin	FITC	all	
from Becton Dickinson and with component H from Invitrogen for dead cell discrimination. Single 
CD27-CD19+IgM+naïve	B	cells,	CD27+CD19+IgM+ memory B cells and CD27+CD19+IgG+ memory B 
cells	were	purified	by	flow	cytometric	cell	sorting	using	machine	FACS	Aria	and	software	Diva	from	
BD. The gating strategy is depicted in Figure 32. 
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Single cell sorting was directly into a 96well plate (thermoquick PCR-Plate Greiner bioOne) with 
20	µl	of	reverse	transcription-buffer	or	Qiagen	OneStep	RT-PCR	reaction	mix	(Qiagen,	Hilden,	Ger-
many)	supplemented	with	0.5	µM	each	of	IgH	chain	V	gene	specific	forward	and	IgG/IgM	reverse	
primers	per	well	208.	Directly	after	sorting,	buffer	plates	were	frozen	on	dry	ice	and	Qiagen	OneStep	
RT-PCR	plates	were	incubated	for	60	min	at	50	°C	for	reverse	transcription	(RT).	After	the	RT	step,	
DNA	polymerase	was	activated	with	an	initial	step	of	15	min	at	95°C.	The	amplification	of	the	result-
ing	cDNA	of	the	Igh	chain	was	performed	at	an	annealing	temperature	of	58	°C	for	45	seconds,	an	
elongation	temperature	of	72	°C	for	1	minute	and	a	denaturation	temperature	of	94	°C	for	30	seconds	
for 48 cycles Non-template controls were included to exclude contaminations in the master mix.
To	reduce	PCR	error	rates	we	used	the	HotStar	Taq	DNA	polymerase	from	Qiagen	with	an	error	rate	
of	2x10-5	/nucleotide	and	cycle.	PCR	amplicons	were	separated	by	electrophoresis	on	a	1.2%	agarose	
gel. To avoid cross contaminations on the gel PCR products were physically separated from each other. 
Bands	with	the	correct	mass	(ca	500	bp)	were	excised	using	individual	sterile	scalpels;	DNA	was	ex-
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A shows the graphic representation of the three B cell compartments, which were single cell sorted into 
a one step PCR mix containing plate. B represents an agarose gel derived from one plate after the PCR 
amplification.	The	correct	mass	of	the	heavy	chain	is	indicated	with	an	arrow.
Figure 33: The sorting and amplification of single cell BCRs
73
FWR1≈75bp FWR2≈51bp FWR3≈114bp
CDR1 CDR3CDR2
D J constant region µ,δ,γ,ε,α
A)
variable region heavy chain≈295bp
http://www.ncbi.nlm.nih.gov/igblast/igblast.cgi
Domain classification requested: Kabat system. 
V(D)J rearrangement summary for query sequence:
Top V gene match Top D gene match Top J gene match Chain type V-J Frame
IGHV3-9*01 IGHD3-10*02 IGHJ5*02 VH In-frame
Alignment summary between query and top germline V gene hit:
from to length matches mismatches gaps identity(%)
FWR1 17 106 90 84 6 0 93.3
CDR1 107 121 15 15 0 0 100
FWR2 122 163 42 40 2 0 95.2
CDR2 164 214 51 43 8 0 84.3
FWR3 215 307 93 86 7 0 92.5
Total 291 268 23 0 92.1
                                                Score    E
Sequences producing significant alignments:    (bits) Value
IGHV3-9*01             383   e-108
IGHV3-9*02                                                                                      380   e-107
IGHV3-20*01                                                                                     332   6e-93
IGHV3-43*02                                                                                     321   1e-89
IGHV3-43*01                                                                                     315   8e-88
IGHV3-48*04                                                                                     300   1e-83
IGHV3-48*03                                                                                     300   1e-83
IGHV3-48*02                                                                                     297   1e-82
IGHV3-48*01                                                                                     297   1e-82
IGHV3-h*02                                                                                      294   1e-81
B) C)
                             <------------------------------------------FWR1-----------------------
                                  E  V  Q  L  V  G  S  G  G  G  L  V  Q  P  G  N  S  L  R  L  S  C  A  
               input seq     17   GAGGTGCAGTTGGTGGGGTCTGGGGGAGGCTTGGTACAGCCTGGCAACTCCCTGAGACTCTCCTGTGCAG  86
                                  E  V  Q  L  V  E  S  G  G  G  L  V  Q  P  G  R  S  L  R  L  S  C  A  
IGHV3-9*01   1    ..A......C......A.............................GG......................  70
IGHV3-9*02   1    ..A......C......A.............................GG......................  70
IGHV3-20*01  1    .........C......A............TG......G......GGGG......................  70
IGHV3-43*02  1    ..A......C......A.............G.............GGGG......................  70
IGHV3-43*01  1    ..A......C......A...........T.G.............GGGG......................  70
IGHV3-48*04  1    .........C......A...........................GGGG......................  70
IGHV3-48*03  1    .........C......A...........................AGGG......................  70
IGHV3-48*02  1    .........C......A...........................GGGG......................  70
IGHV3-48*01  1    .........C......A...........................GGGG......................  70
IGHV3-h*02   1    .........C......A...................A.......GGGG......................  70
IGHV3-h*01   1    .........C......A...................A.......GGGG......................  70
IGHV3-23*04  1    .........C......A...........................GGGG......................  70
IGHV3-23*01  1    .........C..T...A...........................GGGG......................  70
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Sequence analysis: 
A) dark green indicates the variable region and orange the CDRs of the heavy chain. The IgG mol-
ecule is once shown in the native tertiary structure (left site) and in a linear DNA sequence form (right 
site). B) shows the blast result of one representative sequence and the different homology to the ger-
mline sequences in the database (upper part). In the lower part the homology of the different germline 
sequences is represented by the silent and replacement mutations, which can be calculated from the 
sequence (green are silent and red replacement mutations). C) shows the overall blast result with the 
different VH, DH and JH gene families that are used in this particular recombined sequence (upper part). 
The lower part is the output summary of the amount of mutations and the length of the VH, DH and JH 
gene segments. D)	is	the	formula	used	for	the	calculation	of	the	%	bp	exchange.	Where	the	length	of	
the gene segment divides by the number of mutation.
Figure  34: The variable region analysis after 
tracted	(Qiagen	MiniElute	Gel	Extraction	Kit)	and	sequenced.	The	sequenced	variable	region	of	the	
amplified	IgH	chain	were	corrected	with	the	CLC	Main	Workbench	and	analyzed	on	the	international	
immunogenetic information system264,265. The variable region was analyzed for the VH DH and JH usage, 
somatic hypermutations, CDR3 length, isoelectric point and clonal expansion.
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After blasting the sequences clonal expansions were determined by similar CDR3 amino acid (aa) 
sequences and VH DH and JH	usage	(Figure	34	A	and	B).	The	length	of	the	CDR3	is	defined	as	num-
bers of aa starting form the third position after the cysteine motive of the CDR3 and ending at the 
tryptophan amino acid. For the isoelectric point (pI) analysis we used the entire aa sequence of the 
CDR3 and calculated it with the tool on ExPASy proteomics server 266. The VH, DH, and JH gene 
usage was weight balanced by the number of sequences derived from each donor to avoid temper-
ing	 the	 result	 by	 different	 amount	 of	 sequences	 due	 to	 clonal	 expansion	 or	 PCR	 efficacy.	 For	 the	
SHM	analysis,	sequences	were	first	blasted	against	the	germline	sequences	in	the	database	of	IMGT.	 
The blast result of unique CD19+CD27+IgM+ memory B cells in framework- and CDR-regions was 
used	 to	 calculate	 the	%	base	pair	 (bp)	 exchange	by	dividing	 the	number	of	mutations	 through	 the	
length in bp of the individual variable region elements (FWR1, CDR1, FWR2, CDR2 and FWR3) 
(Figure 34 A, C and D).
Expression vector cloning.
Expanded	sequences	were	reconfirmed	via	an	additional	PCR	from	the	pre	sorted	20ul	reverse	tran-
scription-buffer	plate.	The	corresponding	IgL	chain	was	used	to	rule	out	contaminations	and	the	clon-
ing of the antibodies. For this purpose RNA of the single frozen cell was divided into three reverse 
transcription	PCRs	one	for	the	Igh	and	two	for	the	IgL	chain	gene	(lambda	and	kappa).	The	recovered	
heavy chain sequences were then compared to the previous sequences. The corresponding Igh and IgK 
or	IgL	chain	genes	were	cloned	into	expression	vectors	according	to	(Figure	35)	208. The recombinant 
monoclonal antibodies were expressed in 293T cells after calcium phosphate-mediated transfection 
with	22.5	µg	of	each	vector	DNA	(heavy	and	light	chain).	After	3	days,	antibodies	were	purified	from	
cell	 culture	 supernatants	over	 a	protein	G	column.	The	 elution	was	performed	with	0.1	M	glycine	 
pH 2 and dialyzed over night in PBS pH 7.4. 
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single cell FACS
Thaw and devid the RNA  into 3 RT PCR 
spin cells dow in 1x RT buffer and freez imidietly with dry ice
heavy chain light chain κ light chain λ 
reverse transcription reaction with constant  region primers for 1h 50°C
Amplification of the cDNA with the coresponding variable region primers
reaction clean up from a 1.2% agaros gel
L1L2 VH D JH CHg1 L1L2 Vκ Jκ Cκ L1L2 Vλ Jλ Cλ
3’Cλ3’Cκ5433’CHg1
L1L2 VH D JH CHg1 L1L2 Vκ Jκ Cκ L1L2 Vλ Jλ Cλ
3’Cλ3’Cκ5433’CHg1
5’L-VH
primer mix
5’L-Vκ
primer mix
5’L-Vλ
primer mix
Sequencing of the PCR product with the constant region primers
L1L2 VH D JH CHg1 L1L2 Vκ Jκ Cκ L1L2 Vλ Jλ Cλ
3’ BsiWI Jκspec. 3’SalI JH
spec. 5’AgeI VH
3’Xho Cλ  
spec. 5’ AgeI Vκ spec. 5’ AgeI Vλ
restriction digest
VH D JH5’AgeI 3’SalI Vκ Jκ 5’AgeI 3’BsiWI Vλ Jλ5’AgeI 3’Xho
The	map	of	the	target	vector	is	depicted	in	Figure	36		The	figure	is	adapted	from	208
Figure 35: Flowchart for the cloning of single cell derived variable regions into 
        eukaryotic expression vector
76
Specificities	 of	 recombinant	 antibodies	 were	 evaluated	 at	 different	 concentrations	 0.001µg/ml,	
0.005µg/ml,	0.01µg/ml,	1µg/ml,	10µg/ml	and	50µg/ml	using	three	commercially	available	ELISA	kits	
(anti-SPGP	ELISA	kit,	anti-MAG	ELISA	kit	both	from	Bühlmann	laboratories,	Schoenenbuch,	Swit-
zerland	and	an	EBNA1	IgG	ELISA	from	Bio-Rad,	Dreieich,	Germany).	The	ELISAs	were	performed	
according to the manufacturers` recommendations. The OD signal obtained with the negative control 
provided by the manufacturer was subtracted from the OD signals of experimental samples. To detect 
the recombinantly expressed IgG molecules, a goat anti-human IgG secondary antibody coupled to 
HRP	was	used	in	the	MAG	and	SGPG	ELISA	(Sigma-Aldrich,	Buchs,	Switzerland).	The	detection	was	
done	with	TMB	substrate	that	was	stopped	with	1M	H2SO4	and	absorbance	was	measured	at	450	nm.
The unpaired student t-test (two-tailed) was used to compare CDR3 length, isoelectric points, length of 
DH and N elements, and somatic hypermutation frequencies before and after Rituximab treatment. The 
two-tailed Fisher`s exact test was used to compare frequencies of VH gene family usage and the size 
of	clonal	expansions.	All	analyses	are	based	on	individual	sequences	and	data	in	figure	parts	in	which	
error bars are shown are presented as mean ± SEM throughout the manuscript Since we analyzed 
pooled	sequence	data,	a	repeated	observation	analysis	was	not	applied.	A	P	value	of	less	than	0.05	was	
considered	significant.
The study was conducted under a protocol approved by the National Institute of Neurological Disor-
ders and Stroke institutional review board. With informed consent from all patients that were included 
in this study, peripheral blood mononuclear cells were cryo-preserved and used for immunological 
experiments.
Statistics:
Study approval:
ELISA:
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Pat # Clinical Subgroup Age Gender Duration of 
disease (y)
INCAT leg base-
line
INCAT leg 8 
mo
# 8 Placebo 70 M 18 1 1
# 9 Placebo 56 F 10 1 1
# 11 Placebo 69 F 21 1 1
# 13 Placebo 73 F 8 2 2
# 16 Placebo 68 F 8 3 3
# 21 Placebo 53 M 7 1 1
# 3 Responder 61 M 7 2 1
# 14 Responder 72 F 16 2 1
# 15 Responder 69 M 9 1 0
# 27 Responder 71 M 15 4 1
# 5 Non-Responder 70 F 15 3 3
# 6 Non-Responder 64 M 12 2 4
# 10 Non-Responder 73 M 9 1 1
# 12 Non-Responder 69 M 5 0 0
# 17 Non-Responder 59 M 6 1 1
# 18 Non-Responder 76 M 13 1 1
# 22 Non-Responder 76 M 7 1 1
# 23 Non-Responder 71 M 11 1 1
# 26 Non-Responder 47 M 6 1 1
No. Age Gender
# 1 57 M
# 2 60 M
# 3 58 M
Table 6 Healthy control
Table5: Anti-MAG patients
Materials:
The vectore includes the Fc gamma heavy chain, Cytomegalo promoter, SV 40 poly A 
signal and the AMP resistance cassette.
Figure 36: Vector map of the human IgG heavy chain expression vector
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Abbreviations
ADCC  antibody dependent cell-mediated cytotoxicity
AID  activation induced cytidine deaminase
BAFF  B cell activating factor of the tumor necrosis factor family
BCR  B cell receptor
C  cytidine
CDC  complement dependent cytotoxicity
CDR  complementarity determining region
CH1, 2, 3 constant region 1, 2 ,3
CL	 	 constant	region	light	chain
CNS  central nervous system
CSR  class switch recombination
DC  dendritic cell
DH  diversity region heavy chain element
DNA  deoxyribonucleic acid
DSB  double strand breaks
DSB  double strand breaks
EBI-2  G-protein coupled receptor 183
ELISA		 enzyme	linked	immunosorbent	assay
FACS	 	 fluorescence	activated	cell	sorting
Fc R  fragment crystallizable region receptor
FDC  follicular dendritic cell
FOXO1	 fork	head	box	O1
FRC	 	 fibroblastic	reticular	cell
G  guanine
GC  germinal center
HEV  high endothelial venules
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HMGB high mobility group protein
HOXC4	 homeobox	C4
HSC  hematopoietic stem cells 
IC  immune complex
IFN  interferon
Ig  immunoglobulin
IgH  immunoglobulin heavy chain
IGHD  diversity region heavy chain segment
IGHJ  joining region heavy chain segment
IGHV  variable region heavy chain segment
IgK  immunoglobulin kappa light chain
IgL	 	 immunoglobulin	lambda	light	chain
IgL	 	 immunoglobulin	light	chain
Il  interleukin
IRF  interferon regulatory factor
IVIG  Intravenous immunoglobulin
JH  joining region heavy chain element
KDE  kappa deletion element
mAb  monoclonal antibody
MAG  myelin-associated glycoprotein 
MGUS		 monoclonal	gammopathy	of	undetermined	significance
MHC  major histocompatibility complex
MM  medullary macrophage
MRC  marginal reticular cells
MS  multiple sclerosis
MZ  marginal zone
N-elements non-template-encoding-nucleotides
NHEJ  non-homologous end joining
NK  natural killer cell
NMO  neuromyelitis optice
PAMP  pathogen-associated molecular patterns 
PAX5	 	 paired	box	protein	5
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PCR  polymerase chain reaction
PI  isoelectric point
PNS  peripheral nervous system
RAG  recombination activating genes
RSS  recombination signal sequence
RT  reverse transcription 
SEM  standard error mean
SCS  subcapsular sinus macrophage
SHM  somatic hyper mutation
SLE	 	 systemic	lupus	erythematosus
SSM  subcapsular sinus macrophage
T cell  thymus derived immune cell
TCR  T cell receptor
TFH  follicular helper T cell
TGF  transforming growth factor
TLR	 	 toll	like	receptor
UNG  uracil DNA glycosylases
VDJ   recombination variable diversity joining DNA rearrangement
VH  variable region heavy chain element
Xpb-1	 	 X-box	binding	protein-1
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